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Redistributed Manufacturing (RDM) in healthcare has the potential to 
transform the way in which medicines are supplied within the healthcare 
sector. It has the potential to make the system much more resilient and 
responsive and may lead to significant simplification of the supply chain. 
In addition, the use of additive manufacturing systems can completely 
transform how medicines are delivered to patients in terms of both  
new combinations and entirely new formats. The advantages of 
manufacturing medicines specific to a single patient include offering  
a previously impossible level of personalisation. Doses and courses  
of treatment are no longer limited to standard pack sizes, allowing 
therapies to be specifically tailored. The ability to combine drugs in  
a single tablet will improve compliance and the potential to control 
release characteristics offers a new level of complexity. 
The ability of these advances to transform the delivery of medicines 
coincides with the NHS recognising the need to embrace the  
advantages of personalised medicine. In this respect RDM represents  
a critical enabling technology that will be essential if the full benefits  
of personalised approaches are to be realised. Clearly the adoption  
of this technology creates many issues that need to be addressed.  
The way in which medicines are regulated will need to be fundamentally 
rethought and the role of pharmacists in overseeing the process of 
dispensing will be transformed. These are not trivial issues and the  
safety of patients must remain paramount in the introduction of  
this new technology. 
The time to plan for this transformative change is now. The technology  
is rapidly developing to offer new and hitherto unthought-of ways of 
delivering medicines. The challenge will be for all those concerned with 
the supply of medicines to recognise that this change is coming and the 
urgent need to plan for and take advantage of the opportunities it offers.
Mark Bale
Deputy Director, Genomics Science & Emerging Therapies 
Health Science & Bioethics Division 
Public and International Health Directorate (PIHD) 
UK Department of Health
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Welcome to the Redistributed Manufacturing  
in Healthcare Network (RiHN) White Paper. This  
is one of the core outputs of the RiHN, funded by 
the Engineering and Physical Sciences Research 
Council (EPSRC). RiHN brings together a multi-
disciplinary network of academics, stakeholder 
organisations, clinical groups and industry to 
provide a forum to define the challenges of 
realising Redistributed Manufacturing (RDM) in 
healthcare. RiHN provides academic leadership, 
advancing real world applications of RDM in 
healthcare through engagement with relevant 
academic and user communities by conducting 
exploratory sandpit events, user engagement 
meetings, and supporting five feasibility studies 
exploring the potential for RDM in healthcare. 
We take RDM to mean “Technology, systems  
and strategies that change the economics and 
organisation of manufacturing, particularly  
with regard to location and scale” (EPSRC, 2014). 
features of these new ways of working must be 
addressed in ways that enhance quality of life and 
build quality assurance into the business structures; 
and new relationships must be forged between 
suppliers, service providers and users.
The RiHN White Paper is the first dedicated  
report on the RDM landscape in healthcare, 
covering early-stage needs, challenges, and 
priorities. The UK has the opportunity to lead in  
this area, and we have identified an extensive 
number of areas for fruitful R&D, crossing 
production technology, infrastructure, business 
and organisations. The paper serves as a 
foundation for discussing future technological 
roadmaps and engaging the wider community 
and stakeholders, as well as policy makers,  
in assessing the potential impact of RDM.  
Our findings are of particular value for policy 
implementers and funders seeking to specify 
action and to direct attention where it is needed. 
This recognises that the first stage of 
manufacturing evolution was the network of 
localised workshops in small towns and villages. 
The second stage was the creation of centralised 
factories to realise economies of scale. We now 
live in an age where several motives exist for 
redistributing manufacture, including cost 
reduction through terminal customisation;  
just-in-time delivery, particularly of perishable 
healthcare goods; management of capacity  
by distributing production through scale-out, 
rather than scale-up; and reducing up-front 
capital cost by building small production units in 
an incremental response to increase in demand.
There are important research challenges to 
realising these benefits in healthcare industries: 
technical needs must be satisfied to the appropriate 
regulatory standard; new patterns of training and 
retraining must be established to maintain operating 
quality from a distance; social and interpersonal 
The paper is also useful for the research 
community, to support their proposals with 
credible research propositions and to show  
where collaborations with industry and the  
public sector will deliver the most benefit.
Post-Brexit, there are a number of high-profile 
policy drivers increasing the attractiveness  
of RDM. These include the notion of reshoring 
manufacturing capability, further developing 
domestic high value manufacturing and associated 
skill-sets, exploiting opportunities for more 
sustainable and resilient manufacturing 
operations and supply chains, and defining  
a regulatory framework and standards that  
will make the UK a world leader in RDM.
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Executive Summary
Healthcare systems across the globe are under 
pressure to deliver affordable healthcare whilst 
addressing the needs of an aging population,  
and the demand for specialist and novel 
treatments. Events such as pandemics and 
terrorist attacks add more stress to a stretched 
system, impacting quality of patient care and 
healthcare budgets. There is an urgent need  
for cost-effective technologies that can provide 
right-first-time treatments, on demand, close  
to the point of need, reducing the number of 
repeat visits to healthcare professionals and 
avoidable take-up of hospital beds, thus 
alleviating pressure on the healthcare system.
Key priorities for future research and 
development include focusing on:
 1  The development and performance of 
manufacturing technologies (including 
hardware, mechanisation, software,  
and programmable components)
 2  Developing industry consensus on need 
and expectations for the development  
of technical standards for manufacturing 
technologies and critical components
 3  An innovation-centred, systems-based 
model for human capital development  
to support advanced manufacturing 
technology innovation
 4  Quantitative, real-time analytical 
technologies and corresponding data 
analysis tools
 5  The discovery and identification of 
quantifiable measures of product quality
The convergence of new service demands  
with new manufacturing technologies presents 
opportunities to address these challenges, 
particularly as we are heading towards an  
era of therapies that are tailored to individual 
needs and physiological characteristics. The 
potential of innovative technologies and systems 
that bring manufacturing closer to clinical  
need by means of redistributing manufacturing 
represents a transformative departure from  
the current system.
The UK has a strong network of proactive 
research-oriented universities, particularly in the 
fields of medical research and manufacturing 
engineering. However, it has not been clear  
what research is required to realise the potential 
of innovative manufacturing technologies and 
systems that enable local production of medical 
products and therapies. The RiHN White Paper 
represents the first serious attempt to gather 
expertise and to explore applications in promising 
areas of healthcare that could benefit from 
redistributed manufacturing.
 6  Advanced data analytics, machine 
interconnectivity and real-time 
acquisition, management and security  
of multiple sources of data
 7  The potential impact of automated 
production platform technologies on 
product market approval pathways
 8  The impact of emerging healthcare 
sector specific RDM strategies on extant 
legal and regulatory governance 
frameworks
 9  Extending the UK’s ability to provide the 
relevant specialised regulatory science 
skills for emerging manufacturing 
technologies and advanced therapies
 10  Compiling the clinical and economic  
evidence base
 11  Raising the level of organisational 
capability readiness
 12  Formulating alternative financial 
reimbursement models
“ [Re]distributed 
manufacturing  
will disrupt traditional 
labour markets and the 
economics of traditional 
manufacturing.”
WORLD ECONOMIC FORUM (2017)
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The UK Government’s 2013 Foresight Report  
on the future of manufacturing predicted major 
transformations in the nature of production that 
will challenge the healthcare industry. Emerging 
technologies will enable healthcare manufacturers 
to deliver products more rapidly, at a lower cost 
and in a more sustainable manner – “the factories 
of the future will be more varied, and more 
distributed than those of today” (Foresight, 2013). 
How can this be achieved? The RiHN White  
Paper presents a paradigm shift in manufacturing 
termed “Redistributed Manufacturing” (RDM), 
that has the potential to address current 
healthcare system challenges. The redistribution 
of manufacturing in healthcare will involve 
physically shifting manufacturing systems  
closer to the point of clinical need, offering 
healthcare stakeholders increased control  
over quality, quantity and cost. RDM favours  
smaller-scale localised manufacturing units, 
typically enabled by innovative manufacturing 
technologies such as additive manufacturing  
and advanced robotics, complemented by 
advances in diagnostics.
A recent UK government report (Freeman, 2015) 
states that around 222,000 people are employed 
by 5,633 firms across the medical technology  
and biopharmaceutical sectors, generating over 
£60bn per annum. The greatest employment 
growth is in emerging sectors such as digital health, 
which have seen annual growth of 23 per cent 
between 2010 and 2015. Technological advances 
are bringing us closer to realising a more 
personalised form of healthcare, with exciting 
developments in genomics, diagnostics, and 
customised product designs. The ability to 
manufacture devices, advanced therapies  
and medicines at the point of care and need is a 
critical part of this emerging picture, underpinned 
by leading edge developments in precision 
manufacturing (KTN, 2013). RDM is a key enabler 
for the delivery of personalised healthcare, 
potentially accelerating access to treatments  
and superior products. The UK’s strong science, 
engineering and commercial base is well 
positioned to compete in this arena.
1 Redistributed Manufacturing 
in Healthcare
“ The factory of the  
future may be at the 
bedside, in the home,  
in the field, in the office 
and on the battlefield.” 
(FORESIGHT 2013: 20) 
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will significantly impact manufacturing  
practices, particularly as the lines become  
blurred between physical production and point-
of-care service delivery. For example, regulatory 
compliance and quality assurance will need  
to be adapted for multiple locations, making  
it necessary to ensure site-to-site comparability  
of manufacturing, as well as clinical processes 
and handling.
Whilst a compelling driver such as reducing  
costs often takes precedence in manufacturing 
and service organisations alike, a total systems 
perspective is needed for RDM, taking full 
consideration of investment versus return, patient 
benefit, and systemic dependencies that typify 
change and transformation in complex healthcare 
provision. The RiHN programme has examined 
system readiness for RDM in healthcare and 
identified a range of research challenges that 
must be addressed to make the UK a world-
leading and serious contender in this arena.  
Much of this effort requires a targeted approach 
of investing in early-stage technology and 
manufacturing research, which is outlined  
in this White Paper.
Photo U
niversity of N
ottingham
RDM presents a radical way forward for 
incumbent manufacturers to branch into a new 
area, as well as opportunities for new entrants 
and partners to disrupt existing systems. However, 
much of the existing manufacturing infrastructure, 
quality systems, regulatory and governance 
frameworks, business models and organisations 
are tied to traditional modes of operation, typified 
by centralised off-shore mass production and 
large-scale economics. Many past national 
initiatives in manufacturing innovation have 
focused on engineering breakthroughs, such as 
increased automation and robotics on assembly 
lines, and optimising production processes. Whilst 
this may help maintain the competitiveness of 
existing business models, it is sub-optimal for the 
upcoming revolution in personalised healthcare.
“Distributed manufacturing is expected to enable 
a more efficient use of resources, with less wasted 
capacity in centralised factories. It also lowers the 
barriers to market entry by reducing the amount 
of capital required to build the first prototypes  
and products. Importantly, it should reduce the 
overall environmental impact of manufacturing” 
(World Economic Forum, 2015). Whilst there are 
compelling reasons driving RDM, the move from  
a centralised towards a decentralised model  
“ The creation of a new, more dynamic, flexible 
redistributed manufacturing sector may help  
to retain high-skilled graduates in this area. But it  
is likely that this new sector will require graduates 
with skills in STEM as well as business management 
and organisation: educational facilities may need  
to adapt their programmes to provide such skills.”
CAMBRIDGE INSTITUTE FOR SUSTAINABILITY LEADERSHIP (2017) 
Sandpit 
Workshops, 
Bristol and  
Nottingham
Figure 1 Timeline of RiHN events
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RiHN developed a membership database of  
232 individuals who have helped us advance  
the agenda of RDM in healthcare. Around 40%  
of these members are from outside academia,  
with 44 from government and the public sector,  
31 from SMEs, 12 from Large Enterprises, and  
four from other types.
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1.1 The Redistributed Manufacturing  
in Healthcare Network (RiHN)
RiHN brought together a multi-disciplinary team 
of academics and practitioners and delivered  
a variety of workshops covering new areas of 
investigation, technology roadmapping, supply 
reconfiguration and regulation (see figure 1). 
RiHN funded five feasibility studies covering 
potential applications of RDM in areas involving 
cell microfactories and various forms of 3D 
printing (advanced therapies, diagnostic medical 
devices and single dosage pharmaceuticals).
The programme benefited from close 
engagement with the healthcare industry with 
specialists from manufacturing and engineering, 
management, law, consulting, medical devices, 
regenerative medicine, health services, and 
pharmaceuticals (see Appendix C for more 
details). The strength of this White Paper is  
that it combines key stakeholder expertise  
from a range of diverse backgrounds, enabling  
a multi-disciplinary perspective on the future  
of RDM in healthcare.
The team was supported by an active advisory 
steering group, with representatives from 
Innovate UK, Lime Associates Ltd, the Knowledge 
Transfer Network (KTN), and the West of England 
Academic Health Science Network (WEAHSN). 
The advisory group provided expert steering, 
access to key stakeholders, and contributed  
to the independent assessment of feasibility  
study proposals.
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Pharmaceuticals – Future configurations of 
supply chains for drugs and medicines suggest 
RDM could drive down the large-scale waste  
and inefficiencies associated with current  
business operations. Scenario analyses 
considered pharmaceutical manufacturing 
models, such as:
(i) ‘Factory-in-a-box’ – small-scale localised 
manufacture using continuous processing  
models, that require milder processing  
conditions and are more capital/energy  
efficient, that could be replicated in mobile 
‘container’ units supplying local and/or  
niche volume requirements. 
(ii) ‘Print-on-demand’ tableting at selected 
pharmacy outlets for medicines requiring  
multiple dose formats. 
(iii) ‘Make-at-point-of-use’, in the home or in a 
hospital, for selected liquid or semi-solid drugs. 
(iv) ‘Medicines supply and replenishment’ linking 
directly to patient management ‘App data’ on 
usage, and/or diagnostic device data on drug 
efficacy and/or patient medical condition. 
RDM may help bring about a ‘closed loop 
treatment’ system, covering diagnosing patient 
dosage requirements, which would be enabled  
by made-to-order treatments and remote 
monitoring. The current system relies on electronic 
health records and has to deal with issues such  
as low patient compliance.
“ We’re now living in a  
society where customers  
and consumers  
increasingly expect  
a high degree of 
personalisation,  
with bespoke products  
delivered next day  
which meet their  
needs exactly.”
ADDITIVE MANUFACTURING 
STRATEGY (2017)
1.2 Emerging trends
Although RDM has the potential to deliver cost-
effective treatments close to the point of need, 
many challenges remain and intensive research  
is required in the following critical areas:
Medical Devices and Diagnostics – RDM  
could have a significant impact in areas such  
as the manufacture of orthoses and prostheses 
(load-bearing medical devices), providing 
improved products with fit and function  
customised to the anatomy of the patient.  
Through RDM, devices could be manufactured 
within a single visit to the clinic, reducing  
wastage, trauma to patients and associated 
resource costs. This is of particular value when 
fitting orthoses and prostheses for children,  
whose rapid growth often demands frequent 
revisions and alterations. The manufacture of 
specialist diagnostics enabling real-time analysis 
is also a highly desirable outcome, particularly  
in cases where patients can monitor their  
own health.
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In summary, looking across emerging  
applications of RDM in healthcare, there is 
considerable scope to understand the evidence 
base for potential value propositions, allowing  
for a more informed comparison of benefits 
between centralised and redistributed models  
of manufacture. An in-depth analysis of data  
is required related to shelf-life and sensitivity  
of goods, logistical costs, patient outcomes between 
standardised and personalised treatments,  
and total production costs over time. 
Taking RDM into static clinical settings near  
the patient still assumes geographically defined 
operating environments as well as the ability  
to support the treatment of chronic conditions.  
An interesting future possibility would be to take 
RDM into mobile or flexible locations, in cases 
where there is an acute and urgent demand  
for medical products or supplies, for example  
to meet the demands of humanitarian crises, 
natural disasters or emergencies. The first  
hours are critical for saving lives or reducing  
the chances of debilitating conditions; RDM 
systems could seek to deliver rapid diagnosis, 
production and testing in remote conditions.
Healthcare Infrastructure is a critical factor  
in the future development of RDM and raises 
issues around the management of chain of 
custody; assurance of quality; resolving the  
matter of when ‘manufacturing’ becomes 
‘practise of medicine’; suitable models of 
operation with risk-sharing and appropriate 
indemnification by differing organisations;  
and management of training standards for 
operators who are working far from the central 
manufacturer. Consideration of roles, skills  
and communications are key to ensuring that 
changes to infrastructure are considered 
holistically and from a systems perspective.
Regenerative Medicine – the highly specialist 
nature of advanced therapeutic products lends 
itself to RDM. Cell and tissue-based therapies 
(CATBTs) represent a cutting-edge and 
commercially interesting area of medicine  
for treating complex conditions, using living  
cells to restore human body function and  
resolve disease. CATBTs have expensive  
and time-sensitive supply chains. Drivers  
for RDM are primarily related to cost, capital  
and capacity. These include factors such as 
irrecoverable sunk costs in large centralised 
facilities, managing complex supply chains,  
and low temperature transport to ensure  
cell preservation. Responsive manufacture 
coordinated with clinical use is preferred, 
especially if cryopreservation is required.
“ Distributed manufacturing will become the  
norm, with producers augmenting their traditional 
production footprints with smaller and more  
flexible units located next to points of consumption, 
allowing them to meet local requirements with  
a more responsive supply chain.”
WORLD ECONOMIC FORUM (2017)
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3D Bioprinting of Islet Micro-tissues  
to Redistribute Manufacture for 
Treatment of Type 1 Diabetes 
Led by School of Mechanical & Systems 
Engineering, Newcastle University
Diabetes is a global problem contributing to 
escalating healthcare costs worldwide. Ten per 
cent of the NHS annual budget is dedicated to 
treatment of diabetes and its complications. Type 
1 diabetes is typically treated by careful monitoring 
of blood glucose levels and insulin replacement 
therapy. In some cases where glucose is particularly 
unstable, insulin replacement therapy is not enough 
and transplant options must be considered. Islet 
transplantation is a non-invasive ‘micro-tissue’-
based cell therapy presently aimed at restoring 
function by isolating islets of Langerhans from a 
donor pancreas and infusing these islets into the 
portal vein where they engraft and produce insulin. 
Presently, many islets are lost prior to engraftment. 
One of the major driving forces for these losses  
is the highly variable nature of isolated islets. 
The main focus of the feasibility study was to 
develop a method for 3D bioprinting of islet-like 
micro-tissues with the aim of redistributing the 
manufacture of advanced ß-cell replacement 
therapies for the treatment of Type 1 Diabetes 
(T1D). The proposed redistributed manufacturing 
supply chain of ß-cell replacement therapy  
for treatment of T1D has been centred on  
a cost-effective treatment delivery with less  
patient reincidence and expanded access to  
this cell therapy. 
Considering all of the different stakeholders 
involved in the islets’ product supply and transplant 
chain, the proposed modifications will provide  
a more uniform product of greater consistency at 
transplant centres, improving clinician confidence 
as well as patient outcomes. In the short run, this 
will save the NHS money by reducing the number 
of procedures required to achieve this cost-
beneficial treatment. In the long run, the outcomes 
of this project may open this treatment to a wider 
patient pool providing cost-beneficial treatment 
to a much wider demographic.
The emergence of 3D bioprinting provides a  
novel approach to islet transplantation and has 
the potential to improve viability of islets. This tool 
provides a platform to not only improve on existing 
transplant outcomes but to do so in a way that 
satisfies the regulatory need for better defined, 
more homogeneous cell therapies, eliminating  
lot-to-lot and intra-product variability. This provides 
the critical opportunity to define an ideal product 
specification for islet micro-tissue products.
Research Team
A.M. Ferreira-Duarte[1], W.E. Scott III[2], J.A.M Shaw[2],  
A. Popov[2]
[1]School of Mechanical & Systems Engineering,  
Newcastle University; [2]Institute of Cellular Medicine, 
Newcastle University
1.3 Example research projects  
exploring the application of RDM
RiHN funded five feasibility studies exploring 
applications of RDM in healthcare, such as cell 
micro-factories, 3D bioprinting, pharmaceutical 
supply chains, and production of medical  
devices by the consumer (prosumer).
Cell Micro-factories and the 
Manufacture of Cell and Tissue-Based 
Therapies (CATBTs) 
Led by the Centre for Biological Engineering, 
Loughborough University
CATBTs presents a cutting-edge area of  
medicine for treating complex conditions  
using living cells to restore human body function 
and resolve disease. CATBTS have expensive  
and time-sensitive supply chains; responsive 
manufacture coordinated with clinical use is 
preferred, especially if cryopreservation is 
required. Recent attention has focused on cell 
micro-factories – automated manufacturing  
platforms that enable CATBTs to be made  
at a higher degree of reproducibility than  
via manual operation.
The team found that RDM provides opportunities 
for a range of final manufacturing points, from 
regional hubs to small units next to the patient’s 
bedside. Significant developments in online 
monitoring and culture automation are required 
– automated platforms need to digitally monitor 
and manage patient and product requirements, 
but be flexible and replicable. Quality control 
systems must be non-destructive, providing  
close to real-time measurement.
Progressive introduction of small manufacturing 
units to a common design, increasing the  
number of units in response to growing market 
size, is attractive in an economically challenged 
investment environment, overcoming the barrier 
of raising capital and reducing the risk incurred 
when committing all capital costs up-front.
Research Team
J.A. Thurman-Newell[1], J. Petzing[1], P. Hourd[1],  
A. Webster[2], J. Gardner[2], Q. Rafiq[3], R. Harrison[3],  
S. Langron[4], J. Barry[5], A. Wilson[6], N. Medcalf[1]
[1]Healthcare Engineering Research Group, Centre  
for Biological Engineering, Loughborough University;  
[2]Science and Technology Studies Unit, Department  
of Sociology, University of York; [3]School of Life and 
Health Sciences, Aston University; [4]Lime Associates  
Ltd; [5]Cell and Gene Therapy Catapult; [6]CellData 
Services Ltd
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Enhancing the Resilience of 
Pharmaceutical Supply Networks: the 
Role of Redistributed Manufacturing
Led by School of Business, Management  
and Economics, University of Sussex
Posing the questions: “How can the adoption of 
redistributed manufacturing systems enhance  
the resilience of supply networks?” and “Where 
can redistributed manufacturing add the most 
value in pharmaceutical supply networks?” the 
University of Sussex investigated the adoption of 
RDM systems in pharmaceutical supply networks. 
Undertaking an empirical study with participation 
from leading industry experts and academics  
in the fields of innovation, 3D printing/additive 
manufacturing, life sciences and pharmaceuticals, 
the University of Sussex found that pharmaceutical 
manufacturing incumbents are resistant to  
RDM or do not yet recognise the benefits of  
this approach. Because incumbents have  
sunk capital costs in existing infrastructure  
and long-established ways of working,  
RDM poses challenging questions for them.
The researchers suggest RDM should not  
be presented as a replacement, but as a 
complementary model that can run in parallel 
with existing operations, enabling organisations  
to position themselves close to points of need, 
affording greater flexibility, responsiveness and 
resilience. The Sussex researchers advocate 
further proof of concept activities to demonstrate 
the benefits of RDM to the pharmaceutical sector. 
Although RDM is currently regarded as a niche 
activity, research participants from the EPSRC 
Centre for Innovative Manufacturing in 
Continuous Manufacturing and Crystallisation 
(CMAC) and Medicines Manufacturing Industry 
Partnership (MMIP) are exploring the potential  
of RDM to enable localised production of small 
molecules. As discovered by this feasibility study 
and other researchers, a critical factor regarding 
commercial adoption will be the reduction of 
production timescales to meet demand.
Research Team
C. Blome, S. Roscoe
School of Business, Management and Economics, 
University of Sussex
Redistributed Manufacturing  
for Home-use Medical Devices
Led by Regional Medical Physics,  
Newcastle upon Tyne Hospitals
This feasibility study assessed the scope for 
localised, close-to-patient manufacture of 
home-use medical devices, using a single-
patient-use urine flowmeter to develop proof  
of concept. Various additive manufacturing 
technologies were considered and fused 
deposition modelling (FDM), one technique  
used for 3D printing, was found to be superior  
in terms of safety, accessibility of equipment,  
cost and usability. 
Through RDM, the production process for  
medical devices has the potential to become 
leaner, more agile and flexible, enabling a 
‘make-to-order’ rather than a ‘make-to-stock’ 
approach. Having mapped the supply chain  
for the flowmeter case, it was found that shifting 
production close to, or at the point of need/use, 
could lead to time, cost and sustainability benefits. 
RDM could also lead to social benefits: local, 
at-home production reducing the need for 
hospital visits, minimising stress to the patient  
and the healthcare system. However, more  
work is required to overcome technical challenges 
around metrology and human factors related  
to adoption.
Specialist distributed providers (e.g. pharmacies) 
could be first adopters of a RDM model, although 
they would assume the regulatory responsibility  
of a manufacturer. Critical success factors will 
depend on the effective configuration of 
operational responsibilities shared between 
manufacturer innovators, infrastructure owners 
and end-user operators. Ultimately, RDM could 
progress to a point where some devices could  
be manufactured in the home by the patient  
(or prosumer) but production engineers must  
think differently and design for simplicity,  
ease-of-use, and work with materials that  
favour local production.
Research Team
M. Drinnan[1], C. Di Maria[2], A. Bray[1], J. Munguia[3],  
Y. Zhang[3], T. Honey [3], M. Whitaker[4] 
[1]Regional Medical Physics, Newcastle upon Tyne 
Hospitals; [2]Institute of Cellular Medicine, Newcastle 
University; [3]School of Engineering, Newcastle University; 
[4]Faculty of Medical Sciences, Newcastle University
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3D Bioprinting:  
Commercialising Personalised ATMP/
Device Combination Products
Faculty of Engineering, The University  
of Nottingham
Recent developments in bioprinting capabilities 
have made it possible to manufacture customised 
implants tailored to a specific patient. Patient  
data is used to generate 3D models that tailor 
treatments to individual patients. The relatively 
low cost and simplicity of bioprinters make them 
an ideal candidate for RDM. Currently Advanced 
Therapy Medicinal Products (ATMPs) are not 
bio-printed by any businesses. The team at  
the University of Nottingham set out to establish 
the barriers to commercialisation by drawing  
on empirical data collected through engagement 
with a variety of experts including clinicians, 
equipment suppliers and tissue engineering 
researchers. 
The study shed light on the changing roles 
deriving from the novel supply chain, e.g. when 
hospitals become factories, and on how the  
NHS and commercial activities might integrate. 
The research signposted future trends in the 
regulations, raising awareness of opportunities 
and challenges for enterprise in terms of 
emerging business and governance models.  
For example, existing regulatory frameworks  
have not yet addressed the differences between 
products manufactured by bioprinting technology 
and those manufactured by conventional,  
more craft-based methods. With close lines of 
communication with the UK regulator, the study 
contributed to understanding the likely pathways 
that 3D bioprinting can take in the UK and EU.
Research Team
A. Gleadall[1], J. Segal[1], N. Medcalf [2], P. Hourd[2]
[1]Faculty of Engineering, The University of Nottingham;  
[2]Healthcare Engineering Research Group, Centre for 
Biological Engineering, Loughborough University
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Framed by the scope of the feasibility studies, 
each thematic area considers challenges related 
to individual production technologies for 
emerging product candidate groups, focusing  
on process-and system-level aspects that reside 
in the RDM model rather than the product itself, 
except in cases where product-level interactions 
impact the wider implementation pathways  
for RDM. Many of the challenges presented in  
the cell-factory production platform technology 
context are generalisable across the 3D-printing 
technology context.
A summary of the main challenges to realising  
the benefits of RDM across a range of emerging 
applications in healthcare is presented.
2 Needs and Challenges
A comprehensive review of the research material 
generated by RiHN identified future capability 
needs as well as generalisable translational  
and transformational challenges that must be 
overcome if the potential of RDM applications  
is to be realised.
In the healthcare context, RDM will be adopted  
by the development of innovative automated 
multi-product, multi-material, additive layer or 
CATBT production platforms that can be located 
in multiple sites at or near the point of care, which 
is intrinsically dependent on the product type and 
the degree of personalisation. Adopting a systems 
view, RiHN has identified four key interrelated 
challenge themes that distinguish RDM from  
the current centralised production paradigm.
The first two thematic areas describe the 
challenges surrounding the industrialisation  
of enabling production technologies and 
advancing the capability needed for monitoring 
and controlling process and product quality 
(Appendices A1 and A2). The choice of operational 
model, in terms of deployment of the production 
technology in regional hubs, franchises or hospital 
settings, implies different transformational impacts 
on regulatory, business and organisational 
structures. This is reflected in the last two  
thematic challenge areas, which are concerned 
with effective quality management systems  
and how value is created and delivered 
(Appendices A3 and A4).
Production 
Platform Systems 
and Supporting
Infrastructure
Regulation 
and Governance
Analytics
and Metrology
Business 
Models and 
Organisational
Transformation
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For many decades, automation has delivered 
quality and consistency for repetitive processes 
with centralised manufacturing facilities. In an 
RDM scenario, companies or health service 
providers will be responsible for operating  
and maintaining multiple manufacturing 
platforms within hospitals, clinics, or even  
mobile vehicles. This raises the questions: How  
will the redistribution of manufacturing affect 
reproducibility, compliance and comparability? 
How can safety be assured?
For this theme, the following challenges  
need to be addressed.
▶  Overcoming the functional capability and 
performance limitations of existing process 
analytical and product characterisation 
metrology. There is a lack of non-destructive, 
quantitative and rapid analytical methodologies 
amenable to automation and real-time process 
monitoring, control and product release. The 
realisation of RDM is very much dependent on  
the ability to accurately take measurements in  
the context of, for example, starting material 
variation in the case of autologous cell therapies; 
and multiple cellular, physical-chemical, 
geometric and mechanical properties in the  
case of 3D printed products. Current approaches 
require major technological advances to speed  
up the process and instruments of measurement, 
whilst simultaneously allowing easier validation.
▶  Identifying more quantifiable and robust 
measures of product quality that link potentially 
unique personalised or customised product 
characteristics with function (safety and efficacy). 
This relates specifically to the question of what to 
measure. The challenge here is the need to predict 
the impact of manufacturing process on the 
clinically relevant product attributes.
▶  Overcoming technical software hurdles for the 
acquisition, aggregation, analysis, interpretation 
and security of multiple sources of data from 
distributed and interconnected production 
platforms. This is particularly challenging due  
to the scale of data, the different types and 
sources of data that will be generated and the 
need to integrate and analyse this information. 
Leading edge developments from other highly 
regulated industries with similar challenges may 
be transferrable to applications in healthcare.
The fundamental starting point for realising  
the benefits of RDM lies with further science  
and engineering advances in manufacturing 
technologies, looking at how innovative 
production platform systems are integrated  
into the wider healthcare system. Overarching 
issues coalesce around technology and 
manufacturing capability readiness to 
accommodate system flexibility, faster  
low-volume precision, and personalised  
or customised products and therapies  
in a local production facility. 
In this area, the following significant  
challenges have been identified.
▶  Manufacturing technology development  
to overcome the functional performance 
capability and productivity limitations of  
existing bioprocessing and 3D-printing 
technologies and the constraints imposed  
by the need for experienced, highly trained 
personnel and capital-intensive, large  
footprint controlled environment spaces.
▶  High up-front capital costs and long timeframes 
to develop, build and qualify fully automated 
all-in-one production platform system solutions  
in advance of phase III clinical trials and accurate 
market forecasts. Where relevant, this situation 
presents a significant financial investment risk  
and disincentive for innovator and manufacturing 
technology companies.
▶  A lack of industry standards in the supply chain  
is a constraint to standardising production 
platform design, interoperability and assembly  
for operation under Good Manufacturing Practice 
(GMP). There is limited industry supply network 
capacity and capability for responsive supply  
of standardised manufacturing technologies  
and critical manufacturing components 
compatible with a range of raw and starting 
materials. These factors are a critical barrier  
to reducing cost, build times, on-site validation 
requirements and simplifying regulatory review 
processes for adding additional capacity. The 
changing economies of scope and scale enabled 
by RDM and its underlying technologies will 
impact how existing manufacturing industry 
supply chains are reconfigured.
▶  Manufacturing industry and organisational 
systems engineering skills gaps in the broader 
manufacturing workforce. This issue will  
impact innovation and UK competitiveness  
in the design and development of the future 
automated production platforms and additive 
manufacturing systems needed for RDM.
Challenge Theme 1 Developing the enabling advanced production 
platform systems and supporting infrastructure for RDM
Challenge Theme 2 Development of advanced analytics and characterisation 
technology to drive automation of enabling production platforms
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Much of the existing manufacturing infrastructure 
is tied to traditional centralised models of operation 
and economies of scale. Taking a value system 
perspective, moving to decentralised or RDM 
models will have a major impact on the way 
business, organisational and supply chain 
structures need to be designed and integrated  
to create, capture and deliver value.
A range of challenges need to be resolved in 
order to raise the level of institutional readiness 
for RDM in healthcare.
▶  New production platform and service system 
designs are required to assess a suite of future 
desirable operating scenarios. There is a need  
for a more informed comparative evaluation  
of the benefits of RDM to the hospital and the 
broader healthcare system, compared with 
conventional centralised provision. If viable  
routes to market entry are to be established,  
such an evaluation will need to consider barriers 
to technology adoption and to deployment of 
commercial operations in healthcare settings.
▶  Healthcare infrastructure preparedness is a  
major issue given the need to minimise disruption 
to existing infrastructures and healthcare delivery 
systems, and negotiate solutions that incorporate 
the operation of new commercial production 
systems in distributed manufacturing sites.  
There is a need to overcome potential 
infrastructure capacity and capability constraints. 
Also, addressing current gaps in manufacturing 
skills, capability and training for running routine 
operations will be essential for managing new 
ways of working. This is required to ensure and 
maintain operational quality across multiple, 
geographically dispersed manufacturing sites  
and digitally connected responsive supply chains.
▶  A holistic joined-up value perspective is needed 
for RDM, which balances the total costs and 
benefits for the product-service provider, the 
patient population, the customer and the wider 
healthcare system. This is in stark contrast to 
current thinking by manufacturers and health 
service providers. There is a need to understand 
and quantify the cost elements for implementing 
RDM in order to optimise cost structures and 
define commercially viable economies of scale 
and scope. However, commercial pathways  
for RDM will challenge existing conventional 
medicinal product valuation and payment 
models. Alternative financial models will be 
needed that recognise the relative clinical  
and economic benefits, share risk equitably 
between multiple stakeholders, minimise payer 
economic burden and up-front costs and 
ultimately facilitate affordable patient access.
RDM and the innovative production methods  
and digital infrastructures required to enable  
its implementation presents a challenge to 
existing and emerging EU regulatory review  
and governance frameworks (i.e. under ATMP, 
Pharmaceutical and Medical Device Regulations). 
A number of wide-ranging challenges raise  
new questions related to the features of the 
production platform technologies and the 
redistributed model of operation and how  
current regulatory provisions and decision 
processes might be applied or influenced.
▶  Uncertain impacts on product market  
approval pathways, in terms of meeting safety 
and quality standards. Production platform 
technologies present uncertainties related  
to the regulatory governance of customisable 
computer-assisted design and manufacture  
and to closed-system processing in controlled-
not-classified spaces. Advances in real-time 
analytics and characterisation technology,  
by enabling prospective real-time product  
release approaches, are likely to challenge 
conventional end-product testing and batch-
centric regulatory paradigms.
▶  Demonstrating product comparability for 
approval and deployment of additional 
manufacturing sites/machines in different 
geographical jurisdictions presents an 
unsustainable regulatory burden for the adoption 
of multi-centre manufacturing models under 
existing EU frameworks. Likewise, it is unrealistic  
to expect each site operating a machine for the 
production and discharge of licensable products 
to hold a separate manufacturing authorisation.
▶  Managing legal and regulatory implications  
for distributing regulatory responsibilities and 
managing process and product liabilities in  
the shared chain of custody. This affects the 
control, management, governance and security  
of data transferred and shared across sites and 
individuals. The shortage of regulatory and QP 
professionals with the necessary cross-sectoral 
skills and capabilities to administer distributed 
manufacturing sites and advanced therapies  
are likely to exacerbate these challenges.
Challenge Theme 3 Evolution and synthesis of adaptive 
regulatory review, governance and approval pathways
Challenge Theme 4 Developing innovative frameworks  
for business model and organisational transformation
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2 To develop industry consensus on need and 
expectations for the provision of technical 
standards for manufacturing technologies  
and critical components
Industry standards will need to focus on building  
a secure supply chain for compatible manufacturing 
components, materials and consumables. It is also 
crucial to standardise data analytics, machine 
interconnectivity and the real-time acquisition, 
governance and security of multiple sources of data. 
Furthermore, effort will need to be directed towards 
standardising automated production platform 
design, interoperability and assembly to reduce 
cost, platform build lead times, on-site validation 
requirements and to simplify technology transfer 
processes. Lastly, existing material test methods 
may not be applicable for the types of products 
that will be developed via RDM, therefore new 
and existing standards will need to be reconciled.
3 To develop an innovation-centred,  
systems-based model for human capital 
development to support advanced 
manufacturing technology innovation
There is a requirement to benchmark and 
leverage learning from other relevant automated 
production industries to develop responsive 
programmes and delivery mechanisms to advance 
systems engineering and programme leadership 
skills/capabilities. The focus needs to be on 
developing professionals that can act as production 
system architects, capable of integrating early 
and late stage product and process development 
for CATBTs and 3D-printed medicines.
3 Future Priorities
In order to seize the opportunities presented by 
RDM, RiHN proposes a bold R&D agenda that 
incorporates a whole healthcare system view  
of future implementation pathways and wider 
transformation implications. The RiHN-funded 
feasibility studies provided evidence of priorities 
amongst emerging needs, opportunities and 
challenges involved in taking forward future 
healthcare research in RDM. The viability of  
RDM and its successful deployment ultimately 
depends on the identification of credible  
platform designs and sound RDM business 
models. The proposed RiHN R&D agenda  
presents recommendations across industry, 
regulatory affairs and business operations.
The priority areas for future R&D can be 
summarised as follows:
PRIORITY AREAS
▶  Development of Automated Production 
Platform Technologies and Supporting 
Manufacturing Infrastructures
▶  Development of Advanced Analytics  
and Characterisation Metrology
▶  Setting the Framework for Regulatory 
and Governance Pathways
▶  Frameworks for Business Model  
and Organisational Transformation
Development of Automated Production 
Platform Technologies and Supporting 
Manufacturing Infrastructures
1 To support advances in key manufacturing 
technologies and their operational performance 
(including hardware, mechanisation, software, 
and programmable components)
There is a need to move away from incremental 
innovation approaches towards the development 
of high-speed, fully automated, functionally 
closed, GMP-in-a-box platform systems. Such 
platforms must deliver the robustness and process 
capability required to enable the manufacture  
of licensable CATBTs and 3D-printed products  
to be replicated with adequate comparability  
at multiple distributed sites at or near the point  
of care.
The motivation and skills needed to create  
these platforms is unlikely to come from any  
one industrial provider. Rather, the confidence to 
define the user requirements and the momentum 
to develop the technology is more likely to come 
from a pre-competitive community of practice 
comprised of technology providers on the one  
hand, and product and process innovators on  
the other, facilitated by a neutral but motivated 
‘broker’ such as the Knowledge Transfer Network. 
A focus on alternative business models for sharing 
the financial investment risk is also needed.
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Setting the Framework for  
Regulatory and Governance Pathways
7 To assess the impact that automated 
production platform technologies will have  
on product market approval pathways
Engagement with industry and regulatory 
stakeholders is needed to assess how  
product safety and the manufacturer’s ability  
to maintain consistent quality will be affected  
by the unique features of new and emerging 
innovative, fully automated production platforms 
that enable closed processing in controlled- 
not-classified spaces and the potential for  
real-time product release.
8 To assess the impact that emerging  
healthcare sector-specific RDM strategies  
will have on extant legal and regulatory 
governance frameworks
Industry and regulatory stakeholders must  
work together to assess how the regulatory  
and administrative burden for deployment of 
additional sites/machines and the governance  
of multi-centre, digitally-enabled manufacturing 
can be reduced. Also, the implications for 
distributing the responsibility for quality in the 
chain of custody needs to be better understood. 
There must be a robust method for managing  
the integrity and security of data in the shared 
chain of custody and how it can be governed 
across multiple individuals and distributed sites.
9 To extend the UK’s ability to provide the 
relevant specialised regulatory science skills  
for emerging manufacturing technologies  
and advanced therapies
There is a need for industry, with appropriate 
support from academic stakeholders, to lead  
the development and implementation of a talent 
plan to secure a sustained supply of regulatory 
affairs, qualified persons as well as quality and 
production management professionals. This  
will capitalise on and translate the UK academic 
advantage in science and technology research 
into skilled, experienced personnel to support  
the regulation and administration of multiple 
distributed manufacturing sites for the production 
of a wide range of advanced therapies.
Development of Advanced Analytics  
and Characterisation Metrology
4 To advance the development of quantitative, 
real-time analytical technologies and 
corresponding data analysis tools
Appropriate in-process controls need to be 
developed to enable fully automated platforms 
and provide real-time monitoring and active 
control of process and product quality. This 
dictates the need for developing and integrating 
better automated, real-time process analytics 
and product characterisation technologies.
5 To progress the discovery and identification  
of quantifiable measures of product quality
The identification of improved quantifiable 
measures of product quality is necessary to  
link product characteristics with function  
(safety and efficacy) and to in-process controls. 
This is crucial for enabling interchangeable 
manufacturing equipment and for demonstrating 
the ability to manufacture the same product  
at multiple sites with adequate comparability.
6 To advance data analytics, machine 
interconnectivity and real-time acquisition, 
management and security of multiple  
sources of data
Having all unit operations in a single machine 
needs further advances in ‘big data’ technologies 
that can provide data management systems  
that can link patient scheduling, manufacturing 
management systems and chain of custody 
monitoring within and across multiple  
distributed production platforms and sites.
Frameworks for Business Model  
and Organisational Transformation
10 To compile the clinical and economic  
evidence base
There is a clear requirement to develop models  
of clinical and redistributed manufacturing 
processes, and to feed those models with 
quantitative data that will provide a suite of 
statistical operational data. This should take  
into consideration a holistic perspective 
(technology, infrastructure and through-life 
material and support) of both cost and benefit 
data. This will allow for the robust assessment  
of future system designs and scenarios that  
will inform RDM investment and adoption  
in promising applications.
11 Raising the level of organisational  
capability readiness
As manufacturing shifts location towards  
service delivery and closer proximity to patients,  
it is necessary to map the new configuration  
of industrial roles and responsibilities, new  
clinical process models, and associated risks  
and dependencies. Where relevant, the blending 
of boundaries between public and private entities 
raises the need to develop exemplar models and 
test-cases that provide confidence of efficacy. 
This will provide the basis for understanding the 
organisational capability and capacity required  
to further roll-out applications of RDM.
12 To formulate alternative financial 
reimbursement models 
With the disruptive nature of RDM, there is  
a need to consider alternative reimbursement 
models. RDM represents a systemic change 
around the value of the total redistributed  
system. Pricing and cost models need to  
reflect this. This should be well understood  
by manufacturers as the basis for new value 
propositions and communicated effectively  
to healthcare payers and policy-makers.
These high-level summary areas are drawn from the more 
comprehensive and structured ‘system level’ recommendations 
for future R&D presented in Appendix B. These are categorised 
by relevant technology context (cell microfactories, 3D printing, 
and across technologies) and provide detailed guidance for 
funders and researchers seeking to develop future research 
proposals. Each of the tables listed in Appendix B presents 
cross-industry and cross-technology R&D activities needed  
to address the challenges for transitioning technology and 
manufacturing readiness levels within the RDM context. 
Activities are prioritised based on three developmental 
transition phases, which are colour-coded as red (activities  
for early stage transition – concept and feasibility assessment), 
amber (activities for mid-stage transition – technology 
development) or green (activities for late stage transition – 
manufacturing development, production and operational 
deployment). Our approach for the analysis of data and 
formulation of needs, challenges and future priorities for  
R&D is presented in Appendix D.
Cell microfactories 
3D printing
Across technologies
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“ The advent of distributed 
manufacturing and  
its focus on producing 
closer to the consumer 
provides opportunities  
for SMEs to capture  
value through last-mile 
customization, or to 
completely redefine  
their business models.”
WORLD ECONOMIC FORUM (2017)
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RDM has the potential to change the delivery  
of healthcare products, enhancing the UK’s 
national competitiveness and wellbeing of its 
citizens. Promising applications of RDM could 
transform the manufacture of medical devices, 
pharmaceuticals, biopharmaceuticals and 
regenerative medicinal products. However,  
there are key challenges to realising these 
benefits, including: regulatory standards, new 
training patterns, social and human factors  
and quality assurance, as well as the supporting 
organisational structures and commercial 
arrangements. The UK’s strong science, 
engineering and commercial base ensures  
that it is well positioned to compete but, as this 
White Paper highlights, the complex nature  
of the challenges underlines the importance of  
a multi-disciplinary approach, spanning a range  
of traditionally disparate academic specialisms.
Although RDM is at an early stage of development 
RiHN recommends that it should be considered as 
an integrated part of future national manufacturing 
and life sciences strategy, as well as agendas to 
transform healthcare service delivery. For instance, 
RDM presents an opportunity to shape new 
industrial capabilities, attract international talent  
to advance new science and manufacturing 
capability, incentivise investments in infrastructure 
and exploit the potential of digital innovation; which 
are all advocated by the 2017 Industrial Strategy  
for Life Sciences. Future research and investment 
in RDM will benefit from capitalising on existing 
strengths and complementary initiatives in the 
sector that ultimately seek to improve health 
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outcomes for patients and to benefit the economy. 
These include funding for advanced therapy 
treatment centres, as well as MMIP’s ‘Advanced 
Therapies Manufacturing Action Plan’, which  
sets out actions for further investment in  
advanced therapies manufacture in the UK  
and the ‘Manufacturing Vision for Pharma’,  
which aims to focus technology and innovation 
roadmaps towards achieving a step change  
in new medicines platforms. Furthermore, 
advances in remanufacturing engineering will 
present new opportunities for medical products or 
component parts to be put back into local supply 
chains for re-use, thus contributing to the circular 
economy and national sustainability targets.
In the longer-term, RDM is likely to aid the  
delivery of right-first-time healthcare, enabling 
access to personalised therapies, bringing  
the production of medical products closer to 
where it is needed most – in clinics, emergency 
departments, military and medical vehicles, or 
even in areas of conflict or disaster. However, for 
healthcare stakeholders to realise these benefits, 
future research must be directed towards solving 
the challenges and future priorities highlighted in 
this White Paper. Further effort and investment is 
required to reach a position where RDM platform 
systems can deliver medical products rapidly  
to meet demand, at an affordable or lower cost,  
and in a more sustainable manner than existing 
modes of production. Therefore, it is essential  
to support fundamental research in this area  
to ensure the UK is positioned at the forefront  
of RDM in healthcare.
ReferencesSummary
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APPENDIX A – ANALYSIS OF RiHN RESEARCH
A1 Development and implementation of advanced 
production platform systems and supporting 
Infrastructures: Needs and challenges
Cell Factory Product Platform Technologies1
New configurable, portable automated product 
platform systems that permit production of 
multiple, vendor/customer specified, licensable 
products in controlled-not-classified spaces  
at or near the point of care in multiple dispersed 
geographical locations, supporting:
▶  Scale-out of multiple smaller-scale bioprocesses 
for the manufacture of diverse cell types of varying 
batch sizes.
▶  Manufacture of new, lower volume (N=1-100), 
high-value personalised or precision medicines. 
▶  Responsive ‘on demand’ or make to order (MTO) 
manufacture of ready-to-use products.
▶  Simplified verification/validation requirements 
and on-site start-up qualification.
▶  Accelerated product development and launch.
▶  Repurposing for additional unit operations and 
future products.
Agile and reliable supply chains for CATBT 
production system development and supply  
of critical manufacturing components.
 Innovation ecosystem for research and 
development of advanced manufacturing 
technologies.
Setting the incentives for justifying the high capital 
cost and investment commitments for building new 
commercial production platforms and/or facilities 
before clinical trial results or predicable demand. 
Limitations in the relative functional capability  
of existing core upstream and downstream cell 
processing and manufacturing technologies.
Bridging knowledge gaps for expanding the scope 
for automation/mechanisation and integration of 
enabling technologies into configurable closed-
system or portable controlled environments. 
Lack of industry consensus on standards for 
defining requirements for design, assembly  
and validation of configurable ‘GMP-in-a-Box’ 
production platforms and/or portable plants. 
 Lack of sector-specific standards for configuring 
and specifying the interoperability functions  
for connecting upstream and downstream  
unit operations of the production system i.e. 
connectivity of the durable, modular, software, 
programmable and consumable components 
within/across the functional design space.
 Limitations in functional capability of post-
production technologies for maintaining the 
integrity of the finished product at the point of 
product transfer and delivery of ready-to-use 
products for administration.
Technical limitations related to reducing or 
eliminating the consequences of multiple sources 
of intrinsic/extrinsic variation (biological, technical 
and operator).
 Technical and logistical limitations related to 
prolonged time-frames for processing and cellular 
maturation (i.e. to functionally mature cells ready 
for implantation).
Limited sources of supply for compatible and 
interchangeable process-contact manufacturing 
components e.g. most single-use systems are 
proprietary or custom from single vendors.
Minimising on-site inventories for critical raw 
materials and consumables required for multi-
product MTO operations.
Systems engineering and programme leadership 
skills and capability gaps for integrating product 
and process development for manufacture of early 
and late stage cell-based medicines.
Unclear CATBT industry supply network structure 
for the design and assembly of production 
systems, i.e. the machine makers and system 
integrators who supply the Original Equipment 
Manufacturers (OEMs).
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Cell and Tissue-based Therapeutic (CATBT) Products
1 Many of these challenges are generalizable across the 3D printing context.
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3D Bio-Printing Technologies2 3D Printing Technologies2
New configurable automated 3D-printing 
platform systems that permit the design and 
production of a wide portfolio of licensable 
3D-printed products in controlled-not-classified 
spaces at or near the point of care in multiple 
dispersed geographical locations that support:
▶  Manufacture (ex vivo/in vivo) of a range of living 
tissue constructs/organs of varying complexities, 
anatomical geometries and sizes, ready for 
implantation.
▶  High-throughput, MTO manufacture of customised 
patient-matched products, personalised by 
geometry and/or constituent cells.
▶  Ease of changeover between products.
Agile and reliable supply chains for 3D medicines 
production system development and supply  
of critical manufacturing components.
 Innovation ecosystem for research and 
development of advanced 3D-bioprinting 
manufacturing technology.
Fully automated, user friendly 3D-printing 
platform systems that permit the production  
of medical devices in non-classified/dedicated 
spaces in home or primary/ secondary care 
settings that support:
▶  Low-volume, MTO manufacture of non-
individualised (generic), non-implantable  
and disposable diagnostic medical devices.
▶  Easy and safe use by ‘non-traditional’ device 
manufacturers in non-specialised facilities.
Configurable, portable automated 3D-printing 
platform systems for re-designing a wide portfolio 
of existing drug formulations that support: 
▶  Fabrication of solid dosage forms with variable 
densities and diffusivities, internal geometries, 
shapes, multiple actives and/or release profiles 
and doses tailored to the need of individual  
and stratified patient populations.
▶  Scalable, rapid, ‘on demand’ fabrication of 
customised solid dosage forms for immediate  
use in dispersed hospital and compounding 
pharmacies.
Selecting candidate technologies and a unified 
printing approach that shows compatibility with  
a library of materials for fabrication of different  
3D functional tissue constructs or organs of 
varying anatomical geometries and sizes.
Overcoming fundamental limitations in the 
functional capability of existing underlying 3D 
bioprinting technologies, related for example to:
▶  Multi-material printing in the same machine
▶  Scalability (build size and tolerances)  
and shape fidelity
▶  Printing speed, throughput and scope  
of automation
▶  Structural and cell distribution resolution
▶  Aseptic loading/unloading of multiple materials 
during printing processes
▶  Intrinsic cellular sensitivity to fabrication  
materials and processes
▶  Machine-to-machine consistency
▶  Fidelity of the CAD-CAM process chain
▶  Manual post-print processing steps
▶  Coordinating standards development activities 
related to engineering and data interoperability  
of healthcare application-specific 3D-printing 
production processes.
Limited library of available biocompatible and 
bioprintable production-grade raw materials.
Lack of suitable post-production technologies  
that can support the maturation, maintenance  
and delivery of living 3D tissue constructs of 
varying geometries and sizes.
Systems engineering and programme leadership 
skills and capability gaps for integrating product 
and process development for manufacture of  
early and late stage 3D medicines.
Unclear 3D-printing industry supply network 
structure i.e. the machine makers, system 
integrators and OEMs.
 Balancing complexity of device designs with the 
need to simplify the safe installation and operation 
of the user- or patient-centric 3D-printing 
technology in non-specialised/non-dedicated 
infrastructures and facilities. 
Minimising the number of printable parts/sub-
assemblies that need to be manually assembled.
Standardising processes for integrating or 
embedding off-the-shelf electronic sub-assemblies, 
connections and interfaces (non-printable parts).
Eliminating additional manual post-print 
processing of sub-assemblies and the  
finished device. 
Eliminating the risk of printer (hardware  
and software) failure, inadvertent misuse  
or unauthorised use. 
Coordinating the procurement of materials and 
factory-made non-printable sub-assemblies.
Overcoming additional drug-related limitations in 
the functional capability of existing underlying 3D 
bioprinting technologies, related for example to:
▶  Health and occupational hazards (e.g. powder-
based 3D printing).
▶  Tablet surface and morphology imperfections.
▶  Variable mechanical resistance of tablets.
▶  Impact and duration of post-print drying steps.
Incompatibility of different material substrates, 
excipients and active ingredient formulations with 
each other and with the 3D-printing technology 
limit stability and efficacy of 3D-printed solid 
dosage forms and the current application range  
of the technology. 
Limited material choices, colours, and surface 
finishes available for 3D-printing compared with 
conventional tablet compression processes.
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2 Lists specific and additional challenges related to the complexity of each 3D-printed candidate product context.
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A2 Development and innovation of advanced analytics 
and characterisation metrology for coupling product  
and process quality assurance: Needs and challenges
Cell Factory Product Platform Technologies3
Advanced quantitative bio-analytic and 
characterisation metrology tools that support:
▶  Real-time, in-line or at-line process monitoring 
and feedback or closed-loop active control  
of critical process parameters (CPP).
▶  Non-destructive, sampling and/or rapid 
measurement of product critical quality  
attributes (CQA) at the point of release.
 Digital technologies that support analytics, 
integration and management of large data  
sets across sites to:
▶  Enable real-time monitoring and adaptive  
control of multiple CPPs traceable to material  
and product CQAs.
▶  Exploit better understanding of the process  
and the relationship between CPPs, material 
attributes and product CQAs to accelerate  
process and product development times.
Relevant skills/training to support improved 
systems engineering and core data analytical 
Industry 4.0 capabilities.
 Bridging from subjective or semi-quantitative 
metrology to quantitative measurement and 
characterisation techniques to extend scope  
for automation of in- or at-line measurements.
Accelerating innovation in smart sensor technology 
and process analytical technologies to a level  
that supports automation interconnectivity and 
integration into configurable production systems 
to enable in-situ real-time data collection and 
analysis for in-process control and release testing 
of multiple products.
Lack of industry consensus on standards for 
defining capabilities and interconnections for 
managing acquisition, analysis and interpretation 
of large multi-parameter ‘big data’ sets in digital 
manufacturing operations and supply chains.
Specifying more quantifiable measures of quality 
(CQAs) that relate to cell identity and link product 
characteristics to function (safety and efficacy)  
to enable interchangeable manufacturing and 
demonstrate the ability to manufacture the same 
product at multiple sites.
Limitations in the functional capability of current 
analytical methodologies for characterising the 
functional identity of therapeutically relevant cell 
populations at both process and product levels.
Lack of reliable, quantitative potency metrology 
with sufficient levels of resolution (signal/noise 
ratio), precision and specificity that can be validated 
to support in-process, stability and release testing.
Shifting environmental monitoring technology  
to more rapid, real-time analysis approaches. 
Bridging the capability gap for real-time track  
and trace technology across multi-product 
manufacturing facilities and supply chains for 
personalised and precision medicines.
Securing multiple sources of compatible 
(interchangeable) quality assured analytical/
sensor components from different vendors.
Workforce systems engineering and data analytics 
skills and capability gaps across the digital 
operations and supply chain infrastructures
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3 Many of the cellular level analytics challenges are generalizable to the 3D bioprinting context.
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3D Bio-Printing Technologies 3D Printing Technologies
Advanced quantitative process analytical/
visualisation and product characterisation 
metrology that support:
▶  Real-time, in-line or at-line process monitoring 
and feedback or closed-loop active control  
of critical build process parameters (CPP)  
and material attributes (CMA).
▶  Non-destructive sampling and/or rapid 
quantitative measurement of patient-matched 
3D-product critical quality attributes (CQA) at  
the point of release.
 New sector and application-specific champions/
leaders for 3D-printing technology and the new 
era of digitalised computer-assisted design  
and manufacture operations.
Advanced process analytical technologies for 
real-time, in-line monitoring and control of build 
processes that support:
▶  Automated machine quality control and  
self-diagnostic maintenance, calibration  
and troubleshooting routines.
▶  Real-time, in-line process monitoring and 
feedback or closed-loop active control of critical 
build process parameters (CPP) and materials 
attributes (CMA)
Remote quality assurance of individual  
sub-assemblies by the provider.
Advanced quantitative process analytical/
visualisation and product characterisation 
metrology that support:
▶  Real-time, in-line or at-line process monitoring 
and feedback or closed-loop active control of 
critical build process parameters (CPP) and 
material attributes (CMA).
▶  Non-destructive, high-throughput, quantitative 
measurement of multiple, customisable solid 
dosage form critical quality attributes (CQA)  
at the point of release.
 Limitations in the functional capability of current 
analytical methodologies for monitoring and 
quality control of multi-variate physical, geometric 
and mechanical properties linked to the detection 
of design and build errors/flaws in complex  
3D structures. 
Lack of robust bioanalytical metrology tools for 
characterising, tracking and visualisation of cells 
within intact 3D structures and assemblies.
Accelerating innovation in sensor technology  
and process analytical technologies to a level  
that supports automation interconnectivity and 
integration into 3D-printer systems, configurable 
for in-situ real-time data collection for in-process 
control and release testing of multiple, 
customisable 3D-product designs.
Specifying more quantifiable measures of quality 
(CQAs) that link customisable 3D-printed product 
characteristics to function (safety and efficacy)  
or that are predictive of function (product may  
not be in its final form for implantable products).
 Lack of specific industry materials testing 
standards compatible with unique 3D-printing 
and post-print processes (e.g. biocompatibility, 
mechanical testing, etc). 
Lack of multi-scale computational and predictive 
modelling tools limits the ability to define 
appropriate design limits and tolerances that 
describe the entire design envelope (i.e. range  
of each parameter that can be modified) for 
patient-matched 3D-printed implants.
Shifting sterility assurance to more rapid  
non-destructive and/or real-time approaches 
accessible for complex 3D structures with small 
design features or internal porous microstructures.
 Bridging the capability gap for embedding 
real-time track and trace technology into 
customisable, patient-specific 3D structures.
 Educational and workforce level engineering  
and digital design skills gaps needed to advance 
3D-printing technology applications in healthcare.
Defining appropriate design limits and tolerances 
of multiple individually printed sub-assemblies to 
error-proof the assembly process and operation  
of the resulting medical device by non-specialist 
assembler. 
Lack of configurable, intelligent metrology  
tools for in-situ monitoring of critical machine 
operational performance indicators limit the 
ability to detect malfunctions and support  
self-diagnostic, maintenance, calibration  
and troubleshooting routines.
 Standardising the acquisition of patient-matched 
machine and process QC data to provide 
operational transparency and simplify analysis, 
interpretation and supervision of multiple 
3D-printers by remote, trained healthcare providers.
 Lack of industry standards for defining the 
capabilities and interconnections for managing 
the transfer of data between individual patient-
matched 3D-printed diagnostic medical devices 
and remote clinical healthcare providers.
Specifying more quantifiable measures of quality 
(CQAs) that link solid dosage form characteristics 
to function, for instance, related to safe and 
efficacious oral delivery of the API(s) (e.g. purity, 
structural integrity).
Lack of robust, quantitative characterisation 
metrology with sufficient resolution, precision and 
specificity to detect variation/errors in physical, 
chemical, geometric and mechanical properties  
of small heterogeneous solid dosage forms.
Lack of multi-scale computational and predictive 
modelling tools limits the ability to define 
appropriate design limits and tolerances that 
describe the entire design envelope for customised 
solid dosage forms.
Lack of validated characterisation metrology to 
support accelerated stability trials of solid dosage 
forms with multi-API formulations and complex 
release kinetics.
Lack of industry standards for defining the 
capabilities and interconnections for managing 
the transfer of data between the pharmacy, 
patient and the clinician, limiting real-time  
options for adjusting solid dosage form designs  
to prescription or to clinical outcomes.
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A3 Evolution of frameworks for predictable  
and viable regulatory and governance pathways:  
Needs and challenges4
Cell Factory Product Platform Technologies
Evolution and synthesis of adaptive regulatory 
review, governance and approval pathways that:
▶  Accelerate the procurement and licensure  
of new manufacturing capacity. Supporting 
innovative change control and technology transfer 
procedures that allow rapid deployment of CATBT 
production platforms at or near the point of care  
in different jurisdictional geographical markets, 
proportionate to the spectrum of risk.
▶  Harmonise the way regulatory standards and 
building codes are implemented and interpreted 
across different geographic areas and markets. 
▶  Deliver cross-border legal frameworks and 
regulatory provisions that recognise both the 
product and service elements of RDM approaches 
and the obligations of multiple participants 
involved in the production and supply chain.
▶  Support transition to innovative real-time  
process control and product quality assurance 
approaches, applicable to ‘on demand’ 
manufacture and release of patient-centric 
products that can be personalised to individuals  
or stratified patient populations.
 Skills and knowledge ecosystem for specialist 
cross-sector regulatory and QP professionals.
High evidentiary regulatory burden and 
timeframes associated with demonstrating 
product comparability for approval and 
deployment of additional, follow-on 
manufacturing sites/machines in different 
jurisdictional geographical regions (pre-  
and post-MAA).
Impracticalities and sustainability of the need  
for each host site operating a machine for the 
production and discharge of CATBT products  
to hold a separate manufacturing authorisation.
Delineating the regulatory and legal obligations  
of the MAA licence holder and the host sites 
(hospital/franchise) for traceability and record 
keeping in the chain of custody throughout each 
product’s lifecycle.
Impracticalities and sustainability of the 
requirement for the physical presence of  
a QP at each host site.
Sustaining consistent governance oversight  
of manufacturing and QC steps across multiple  
sites/machines. 
Maintaining consistent levels of training/
competency to ensure compliance across  
all host sites.
Delineating the scope of product and process 
liabilities in the shared chain of custody.
Uncertainty related to the impact of Brexit on the 
future regulatory environment and consequences 
for UK manufacturing and supply chains.
Standardising automated platform design  
and validation criteria for producing multiple 
licensable products under divergent geographical 
clinical, manufacturing and supply chain 
regulations.
Uncertainty related to regulatory acceptability  
of closed-system processing in controlled-not-
classified spaces.
Incompatibility of real-time release testing 
approaches with batch-centric regulatory 
paradigms.
Impracticalities of managing retained/reference 
samples for complex individualised and MTO 
products.
Unresolved questions around regulatory/legal 
governance of the digital infrastructure required 
for the control, management and protection  
of data across multiple sites/machines. 
Minimising concerns related to unauthorised 
production, off-label prescribing, adulteration  
or mix-up of treatment regimens.
Additional compliance complexity related to  
the in-situ, ‘on demand’ personalised packaging 
and labelling of multiple individual products.
Long-term effects related to the disposal of  
single-use components used in bioprocessing.
Skills/knowledge gaps for provision of specialised 
roles in the regulation and administration of 
advanced therapies and manufacturing facilities.
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4 Based on constraints under the scope of the current regulatory frameworks; where the main novelty  
resides in the process of manufacture rather than the product itself. Generic product-specific challenges  
or those related to precision medicine or to pre-clinical or clinical trials are therefore not considered.
50  RiHN RiHN  51
3D Printing and 3D Bio-Printing Technologies5
Absence of distinct 3D-printing legislation  
raises uncertainties/ambiguities related to 
delineating the extent existing regulatory regimes/
standards and emerging regulatory reforms  
apply to the 3D printing, post-print processes  
and 3D-printed products.
Impracticalities and sustainability of the implied 
need for each host site operating a 3D printer for 
production and discharge of 3D-printed devices/
products to hold a separate manufacturing 
authorisation. 
Current IP/security methodologies and legal 
systems are not appropriate for digital networks 
and ways of working required for 3D printing. 
Minimising product liability exposure risks  
related to the control of customisable CAD/CAM 
processes and the involvement of multiple 
participants in the production and supply chain.
Uncertainty related to where the limits of 
regulatory authority lie for the design and 
manufacture of customisable 3D-printed  
products in hospital and pharmacy settings.
Impracticalities of managing retained/reference 
samples for complex, customised (‘batch of one’) 
3D-printed products.
Unique build processes and multiple design 
variations of customisable 3D-printed products 
render conventional design process verification 
and validation approaches difficult to apply.
Establishing acceptable procedures for oversight 
of post-print finishing processing and/or manual 
assembly of the finished 3D-printed device by 
untrained, non-specialists in home settings.
Unifying Quality Systems across industry GMPs 
(Pharma, Medical Devices, ATMPs) to direct, 
control, and coordinate the quality of multiple 
3D-printed product lifecycles. 
Minimising regulatory concerns related to 
unauthorised printing, illicit use of raw materials 
and potential for mix-ups in patient drug or dosing 
treatment regimens.
Establishing the regulatory scope for combining 
3D-printing with conventional drug manufacturing 
lines for producing a wider range of compounds 
during drug development and clinical trial.
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Evolution and synthesis of adaptive regulatory 
review, governance and approval pathways that: 
▶  Accelerate the procurement and licensure  
of new manufacturing capacity. Supporting 
innovative change control and technology  
transfer procedures that allow rapid deployment 
of 3D-printer production platforms at or near  
the point of care in different jurisdictional 
geographical markets.
▶  Deliver cross-border legal frameworks and 
regulatory provisions that recognise both the 
product and service elements of RDM and define 
the obligations of the designer, the equipment  
the producer/owner/supplier, the manufacturer 
and the consumer within the liability spectrum. 
▶  Support innovative real-time quality assurance 
approaches applicable to unique 3D-printer build 
processes and to divergent classes of 3D-printed 
products that can be customisable in the ‘on 
demand’ computer-aided design and 
manufacturing process.
▶  Support computer-aided design and manufacture 
of 3D-printed products proportionate to the 
specific product type, classification and risk to  
the patient, e.g. ranging from active implantable 
devices or medicinal products, drug delivery 
systems and non-active implantable devices  
to non-implantable devices.
▶  Support the delivery of sustainable eHealth  
and data protection systems.
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5 Lists additional and specific challenges related to the regulation of 3D printing.
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Formulation of a compelling value proposition 
based on the design and integration of the 
product (core platform technology and 
accompanying modular, digital and 
consumable components) and service 
offering (compliance & security components). 
Maximising the creation, capture and delivery 
of value for customers (healthcare providers, 
payers and users) and patients in primary 
and/or secondary care settings.
Identifying the most promising production 
system design and options for configuring  
the mode of operation (e.g. via hub, franchise, 
hospital) that delivers maximum value-add 
(the ‘sweet spot’ for converting the value 
proposition into sustainable revenue  
streams in the RDM landscape).
Identifying patient populations and candidate 
product group profiles where development 
efforts should be targeted and economies  
of scope can be leveraged to maximise 
patient benefit, healthcare system  
benefit and reimbursed price potential  
(the solution space).
 Identifying viable market channels and 
predicting the scale of target customer  
and market demand for the enabling 
production technologies.
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Therapy Medicinal Products (ATMPs)
▶  Diagnostic Medical Devices
▶  Solid Dosage Forms
A4 Developing innovative frameworks for  
business model and organisational transformation:  
Needs and challenges6
Cell Factory Platform, 3D Bio-Printing  
and 3D Printing Technologies
 Creation of customer interfaces and ways of 
working to establish viable routes to market 
entry and create pathways to adoption and 
delivery of value to customers and patients.
Digitalisation and integration of vertical  
and horizontal value chains to optimise 
collaborative relationships.
 Configuration of the value system to deliver 
the value proposition and maintain customer 
interfaces.
Development of the business-critical 
capabilities and partnership networks needed 
to transform the organisational capability 
readiness of the supplier (equipment provider) 
and the customer (as the manufacturer at  
the host site) for carrying out the activities 
necessary for creating and delivering value.
With little heritage of experience, the level  
of implementation challenge to local, regional 
and national healthcare systems and traditional 
professional constructs introduces significant 
barriers to adoption of manufacturing 
technologies and commercial manufacturing 
operations in hospital settings.
Forming long-term collaborative partnership 
and transactional arrangements with the 
health service provider to build a viable 
business model for the hospital and embed 
the required capacity and supply chains for 
commercial RDM operations (i.e. via hub, 
franchise or hospital).
Overcoming healthcare system barriers to  
the implementation and delivery of customer-
centric servitisation strategies. 
Building and maintaining digital trust in 
continuous data flows that result from vertical 
and horizontal value chain networks.
Existing levels of institutional readiness  
in healthcare limit opportunities for 
standardising technology transfer 
methodologies.
Bridging existing physical infrastructure 
constraints/gaps to raise the level of facility 
readiness at distributed host sites for 
installation, set-up and operation of supplied 
commercial cell micro-factory or 3D-printing 
production systems.
Bridging digital infrastructure constraints/
gaps to raise the level of interconnectivity 
within existing healthcare infrastructural 
networks and between the central and host 
site to aid delivery of servitisation strategies.
Addressing the core human resource 
capability and capacity constraints/gaps  
at distributed host sites, including the need  
for manufacturing technicians/operators and 
essential personnel (QP, production managers, 
QC controller and responsible persons).
Minimising the level of organisational change 
or disruption to existing treatment algorithms 
and healthcare delivery processes.
Minimising the administrative/regulatory 
burden and exposure to regulatory compliance 
risk at each host site in the network. 
Establishing centralised training centres  
(i.e. with identical equipment/facility 
configurations), providing access to 
standardised operational and compliance 
training for operators/technicians running 
routine manufacturing operations at 
distributed host sites.
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6 Several business model configurations are possible depending on the operational model and the level of servitisation  
and customisation. Each configuration may raise different challenges. The following table considers challenges that  
are generalisable to both cell factory and 3D printing contexts. Specific challenges related to the choice of cell lines,  
the use of an intermediate cell banking step or co-development of companion diagnostics are not considered.
Cost structures that support commercially 
viable economies of scale and scope, in  
line with the demonstration of value and 
market growth.
 Build innovative and flexible payment, 
financial and EU market access models that: 
▶  Recognise and translate customer value 
(clinical and economic) into sustainable and 
highly profitable incoming revenue streams.
▶  Balance risk and financial exposure of  
payers with differing value/cost drivers  
across multiple geographies. 
▶  Enable patient access to affordable new 
therapies and minimise economic burden  
of patients and healthcare providers.
Defining realistic total cost/benefit thresholds:
▶  Dearth of information for monetising the 
fixed/variable costs of operational business 
models, making it difficult to predict the 
investment needed for translation.
▶  Unpredictable revenue, cost and efficiency 
gains related to the servitisation elements  
of the value creation process.
▶  Uncertainties related to valuing (£) and 
demonstrating long-term clinical and 
economic impact/benefits (added value)  
of the product-service offering to the patient 
population, to the hospital and the broader 
public and private healthcare systems.
Unpredictable rate and volume of market 
penetration/expansion weakens strategies  
for mitigating high financial investment risk in 
capital equipment acquisition or facility build. 
Rationalising reimbursement and pricing 
strategies, in terms of the holistic value 
framework for the patient population and  
the healthcare system at local, regional  
and national levels.
Geographical variation in the relative 
importance of clinical and economic 
considerations and type of health  
economic framework applied. 
Added market access and economic 
uncertainties related to the evaluation  
of low volume personalised, customised  
and potentially curative medicines and  
the requirements for accompanying 
interventional procedures.
Dispersed ownership of the chain of custody 
challenges conventional reimbursement  
and payment frameworks.
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APPENDIX B – PROPOSED RESEARCH  
AND DEVELOPMENT AGENDA FOR 
REDISTRIBUTED MANUFACTURING
B1 Science, Research & Development  
Priorities for Redistributed Manufacturing
Develop and Implement Advanced Production 
Technologies and Manufacturing Infrastructure
I1 Building the manufacturing infrastructure and workforce
Translate and capitalise on learning from other 
automated production industries (e.g. automotive, 
electronics industries) to develop a talent plan for 
securing the systems engineering and programme 
leadership skills and capabilities needed for 
integrating early and late stage product and 
process development programmes for CATBTs  
and 3D-printed medicines.
Establish industry working group with component 
suppliers to identify opportunities for standardisation, 
improving compatibility between different vendors 
and shortening lead times for critical production 
components (e.g. single-use devices and 
connectors). The aim is to create an agile and 
reliable digital supply chain to minimise on-site 
inventories and ultimately reduce facility footprints.
Establish an industry group to map the global Cell  
& Tissue Based Therapy (CATBT) industry supply 
network structure (the machine makers, the system 
integrators and OEMs) to identify the capacity  
and capabilities of the industry for the design  
and assembly of CATBT platform production 
systems. The aim is to determine the technology 
gaps and UK strategic priorities with respect to 
building a robust supply chain and long-term  
RDM capability in the UK.
Establish a multinational working group to  
explore the equivalency of the UK/EU clinical, 
manufacturing and supply chain regulatory (and 
building) standards and the links to the clinical 
constraints for distribution and deployment of 
manufacture to each region. The aim is to provide 
the technical basis for deriving unified guidance to 
support the design and development of production 
platform systems that can be specified for transfer 
and deployment in multiple geographical locations.
Drawing upon the regulatory equivalency exercise, 
establish a pre-competitive community of practice 
(comprising technology providers and product/
process innovators) to identify common user 
requirement specifications (URSs) as a technical 
basis for the rational design of automated, 
3D-printing production platforms for the 
manufacture and delivery of 3D-printed products. 
The aim is to provide a platform for knowledge 
transfer and the motivation and skills needed to 
advance the functional capability maturity and 
scope for automation/mechanisation of candidate 
3D-printing platforms.
Drawing upon the regulatory equivalency exercise, 
establish a pre-competitive community of practice 
(comprising technology providers and product/
process innovators) to identify common user 
requirement specifications (URSs) as a technical 
basis for the rational design of automated 
production platforms for the manufacture  
and delivery of CATBTs. The aim is to provide a  
platform for knowledge transfer and the motivation 
and skills needed for the collaborative development 
of these production platform technologies and  
their supporting manufacturing technology  
supply chains. 
Cross-industry foresight review of the high-value 
manufacturing innovation landscape to identify and 
evaluate opportunities for advancing the functional 
capability maturity and scope for automation/
mechanisation and integration of core upstream 
and downstream cell processing and manufacturing 
technologies. The aim is to identify the mainstream, 
maturing and emerging technologies that can be 
prioritised or monitored for future application in  
cell micro-factory production systems.
Establish an industry group to map the global 
3D-printer technology supply network (the  
machine makers, system integrators and OEMs)  
to identify the capacity/capability of the industry 
and evaluate the maturity level of the systems that 
may be integrated into future platforms solutions  
for healthcare applications. The aim is to determine  
the technology gaps and identify UK strategic 
priorities with respect to building robust supply 
chains and long-term 3D-printing manufacturing 
capability in the UK.
Widen industry engagement with relevant 
standards-setting organisations to extend  
and coordinate the development of specialised 
technical standards for defining requirements  
and specifications for the design, engineering  
and interoperability of autonomous 3D-printer 
production platforms (and associated test/
validation procedures) for relevant sector-specific 
processes and applications.
I2 Advancing production system technology readiness
Advance the interoperability of 3D-bioprinting 
technology in specific areas that support 
automation and integration of aseptic cellular 
processing steps and/or cell delivery sub-systems 
into configurable production systems to improve 
user interfaces.
Extend material science enabled advances in  
the discovery, design and engineering of chemically 
defined synthetic material and biomaterial  
(bioinks) substrates to expand the library of  
stable biocompatible and printable production-
grade materials.
Advance the capability and interoperability of  
the computer-aided design to manufacture chain 
(CAD-CAM step). The aim is to provide better 
control of multiple translation and compilation  
steps and reduce the potential for errors in design 
input translation, while providing simplified  
and easier to use software that can be configured  
or customised for application-specific design 
models and printing processes.
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I3 Advancing post-production system technology readiness
Advance the functional capability maturity  
of post-production technologies to extend 
opportunities for automation and process 
integration, focusing on scalable closed-system 
technologies for detecting and selectively 
eliminating unwanted cells, fill and finish 
technologies and standardised technologies  
for product transfer, delivery and administration.
Advance the scalability and functional  
capability maturity of post-production bioreactor 
technologies in specific areas that accommodate 
prolonged time-frames for complex cellular-
material remodelling and maturation and support 
the maintenance and delivery of living 3D tissue 
constructs of varying geometries and sizes.
Advance the functional capability maturity of 
post-production technology in specific areas  
that support automation and process integration  
of additional post-print treatment processes  
(such as drying steps) into configurable 3D-printing 
production systems for solid dosage forms. 
Extend industry engagement with relevant 
standards-setting organisations to determine  
the applicability of current international standards 
and EU pharmacopoeia material test methods  
to 3D-printing processes (e.g. biocompatibility, 
mechanical testing). The aim is to explore state- 
of-the-art and identify the required actions to 
reconcile standards applicability gaps that  
relate to real-time release testing approaches  
and to the customisability and unique build 
processes of 3D-printed products/devices,  
including post-print processes such as cleaning, 
finishing and sterilisation.
Drawing on the quality standards development 
exercise, explore strategies for implementation  
of an external, centralised QA scheme/service 
based on, for example, the periodic introduction  
of standardised fabrication protocols/reference 
materials into distributed 3D-printer production 
systems. Aim is to enable trending and proficiency 
testing of design and build performance across 
multiple 3D-printer platforms and sites.
Establish a working group, in collaboration with  
the relevant standards-setting organisations,  
to consider the challenges for standardising the 
interoperability of data and machines, the use  
of data to support manufacturing decisions, 
governance in the digital environment and model 
performance validation. Aim is to develop a sector-
specific view and consensus on requirements for 
developing standards to encourage collaboration 
and data sharing in RDM supply chains.
Establish a working group, in collaboration with 
relevant measurement organisations, to consider 
the technical requirements for development and 
specification of machine calibration/reference 
materials, reference standards for analytical test 
methods and data reference sets for data  
analysis, presentation and interpretation. Aim is  
to develop a framework for comparative analytics 
and the provision quality standards across the  
RDM network.
Drawing on the quality standards development 
exercise, explore strategies for implementation of 
an external, centralised QA scheme/service based 
on, for example, the periodic introduction of positive 
and negative quality control and/or calibration 
material into distributed micro-factory platform 
manufacturing processes. Aim is to enable  
trending and proficiency testing of manufacturing 
and analytical performance (independent of 
product lots) to confirm that processes and methods 
remain in a state of operational control across 
multiple sites. 
I4 Building digital Quality Assurance infrastructures
B2 Priority Research & Development for Analytics and 
Metrology Science for Redistributed Manufacturing
Analytics and Metrology Science Research & 
Development Priorities for Redistributed Manufacturing
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I5 Advancing in-line monitoring, process  
characterisation and control technology readiness
I6 Advancing product characterisation, CQA  
testing and measurement technology readiness
Review the high-value manufacturing innovation 
landscape in other relevant sectors (e.g. pharma/
biopharma/food industries) to identify opportunities 
to transfer best practice and/or exploit advances  
in digital technologies, sensor devices, data 
analytics, data integration and management across 
production platforms and the RDM value chain.
Pre-competitive benchmarking activity to extend 
opportunities for specifying more quantifiable 
measures of quality (CQAs) that link cellular product 
characteristics to function (safety and efficacy).  
The aim is to provide the basis for developing  
the industrial metrology needed to enable 
interchangeable manufacturing and enhance  
the ability to manufacture the same product  
at multiple distributed sites.
Advance the development of real-time, non-
destructive process analytical technology (PAT)  
and non-invasive, quantitated imaging technologies 
that can provide the basis for precise real-time 
monitoring and feedback control of CPPs, are 
compatible with in-line automation and are  
immune to scalar effects. Aim is to transition from 
end product testing and tightly controlled CPPs  
and CMAs to automatic real-time testing and 
flexible CPPs to respond to input variation.
Develop robust, simplified and quantitative product 
characterisation metrology with enhanced levels  
of resolution (signal/noise ratio), precision and 
specificity. The aim is to provide the basis for the 
initial development of a panel of ‘For Information 
Only’ tests that can be validated and transitioned  
to support in-process control, stability testing  
and product release and, where possible, can  
be standardised across product groups. 
Establish a collaborative working group with  
OEMs to specify and advance the functional 
capability of biosensor and in-situ real-time  
process bioanalytical and quantitated imaging 
technologies for tracking and visualisation of  
cells and contaminating biological organisms  
within intact 3D tissue construct structures.
Explore direct (e.g. introduction of labelling  
agent into cells) and indirect (e.g. introduction  
of reporter gene) labelling and molecular imaging 
modalities as a basis for the development of 
real-time cell tracking capability amenable  
to automated visual inspection, both in-process  
and after clinical administration.
Investigate the application of Quality by Design 
(QbD) methodologies to evaluate the relationships 
between process parameters, material attributes 
and product properties for representative case 
studies. The aim is to establish ‘generic-level’  
critical process parameters (CPPs) that should  
be monitored during production and to define  
the metrics and in-process analytical tools that 
apply and that can be extended to specific  
cell-factory applications.
Pre-competitive benchmarking activity to extend 
opportunities for specifying more quantifiable 
measures of quality (CQAs) that link 3D-printed 
product characteristics to function (safety and 
efficacy) or are predictive of function (product  
may not be in its final form when implanted)  
for representative cases.
Investigate the application of QbD methodologies to 
evaluate error/failure modes and the relationships 
between process/build parameters, the material 
attributes and the final product properties in 
representative case studies. The aim is to establish 
the ‘generic-level’ CPPs and critical material 
attributes (CMAs) that should be monitored during 
production and to define the metrics and in-process 
analytical tools that apply and that can be extended 
to specific 3D-printing applications.
Advance the development of sensor and control 
devices that can be incorporated or embedded into 
ex vivo 3D niches to add new levels of functionality 
to 3D structures and provide real-time monitoring 
and remote control of niche components  
within 3D assemblies (e.g. remote actuation  
or active modulation).
Develop enhanced multi-variate data mining and 
advanced pattern recognition analytics capability  
to facilitate identification of CPP relationships with 
critical quality attributes (CQA). Aim is to provide  
the basis for the design and development of closed-
loop control systems.
Develop in-situ cell-specific sensor platforms 
(disposable/reusable) with plug-and-play options 
for different cell types, which can be applied to the 
real-time in-line measurement of CQAs at cellular 
and sub-cellular levels. The aim is to extend 
opportunities for predicting the quality of  
cellular starting materials, intermediates  
and drug substances.
Establish a collaborative working group with OEMs 
to specify and advance the functional capability  
of in-situ sensor and in-process analytical and data 
acquisition technologies that can support real-time 
monitoring and closed-loop control of multi-variate 
physico-chemical, geometric and mechanical 
properties. Aim is to enhance the ability to detect 
and mitigate build errors/defects and reduce or 
eliminate the need for post-print processing steps.
Advance the development of monitoring  
subsystems that allow real-time and high  
resolution determination of drug dosing.
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I7 Advancing assurance of manufacturing quality I8 Advancing data management and information technology readiness
Advance the development of next generation 
multi-scale computational and predictive modelling 
tools. By linking multiple design, manufacturing  
and materials attributes, the aim is to enhance 
understanding of 3D-printing error budgets  
and provide the ability to predict outcomes and 
define appropriate design limits and tolerances  
(i.e. for verifying that the finished product meets  
the design inputs).
Develop generalisable process maps of all data 
sources across the process/product workflow  
for representative RDM case studies and digital 
scenarios. The aim is to identify the touch-points 
where data is collected and exchanged across  
the vertical and horizontal value chain to provide 
the basis for a data and information technology 
asset requirement and capability gap analysis.
Explore and develop a standardised mechanism  
for testing the consistency of 3D-printing builds, for 
instance, design and manufacture of representative, 
standardised constructs or coupons with each build 
to detect build variations.
Investigate new methodological approaches  
for building standardised design control models  
for customised 3D-printed devices to enable  
design verification and design validation steps  
to be incorporated into the overall design and 
manufacturing process. The aim is to adapt 
approaches from GMP and existing bracketing/
matrixing approaches to develop standardised 
‘worst-case’ performance challenge methodology 
for addressing the numerous design parameters 
that can be customised based on user needs  
(i.e. accommodating design envelopes with  
an infinite number of design variants). 
Drawing upon the digital asset and capability gap 
analysis, establish a working group to explore the 
information technology and Industry 4.0 landscape. 
This is to identify and evaluate opportunities to 
exploit existing and emerging digital platforms and 
sensor-enabled software solutions for managing 
and securing the real-time acquisition, aggregation, 
analysis and interpretation of multi-parameter  
data streams from manufacturing processes and 
workflows across multiple sites. The aim is to map 
out an Industry 4.0 strategy that can improve 
business processes and build digital trust.
Explore and develop predictive modelling 
approaches and methodologies as surrogates  
for design validation of customisable 3D-printed 
devices and for modelling future states of the 
device, such as growing tissues or material 
degradation under challenge conditions  
(e.g. Finite Element Analysis for predicting 
mechanical performance).
Advance the development of scalable and 
compliant product serialisation technology  
(e.g. RFID, watermarking technologies) that can  
be integrated into cell micro-factory and 3D-printer 
production lines to provide a holistic approach  
to product tracking and traceability across  
supply chains. The aim is to address the need  
for real-time visibility into where a specific 
individual product physically resides in the 
downstream supply chain in order to recognise 
counterfeit situations, identify expired products  
and perform targeted recalls, i.e. moving away  
from batch-centric materials management.
Advance the development and application of 
multi-variate statistical process control and other 
statistical projection concepts and techniques  
for real-time monitoring of agile production  
systems and for situations where products  
are manufactured in small batch sizes or  
can be customised within process. 
Advance the development of non-destructive 
methodologies for testing the efficiency of post-
manufacturing cleaning and sterilisation processes 
and their impact on the fidelity of the final 
manufactured device.
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B3 Regulatory Science Research & Development  
Priorities for Redistributed Manufacturing
Setting the Framework for Regulatory and  
Governance Pathways
R1 Developing a viable regulatory strategy
Establish an industry group, with appropriate 
support from academic stakeholders, to lead  
the development and implementation of a talent 
plan to secure a sustained supply of regulatory 
affairs, qualified person and quality/production 
management professionals. The aim is to capitalise 
on and translate the UK academic advantage  
in science and technology research into skilled, 
experienced personnel to support the regulation 
and administration of multiple distributed 
manufacturing sites for the production of  
a wide range of advanced therapies.
Leveraging learning from recent approvals (e.g. 
Aprecia Pharmaceuticals ZipDose® Technology), 
establish a working group to explore the regulatory 
scope for combining 3D-printing with conventional 
drug manufacturing lines to extend the flexibility  
in the production of a wider range of solid dosage 
forms during clinical trials.
Drawing on emerging solutions in the precision 
medicine space, engage with appropriate 
stakeholders to explore the legal, ethical and 
regulatory challenges for the governance of  
the implied digital assets and infrastructures 
required for the control, management and 
protection of data that may be transferred  
and shared across multiple sites, stakeholders  
and machines in the RDM operational context.
Drawing upon representative 3D-printing case 
examples, engage with appropriate stakeholders to 
identify the regulatory/liability boundaries between 
the customisable manufacturing process and 
practice of pharmacy to delineate the distinction 
between compounding and manufacturing and  
to define specific activities that lie outside the 
bounds of regulatory jurisdiction.
Establish a working group to delineate the extent to 
which existing regulatory regimes (medical devices, 
pharma, ATMP) and emerging reforms (e.g. new  
EU MDD, EU Falsified Medicines Directive, General 
Data Protection Regulation) apply to the 3D-printing 
machine, the controlling software and process  
(CAD to CAM chain), the component materials  
and the 3D-printed product itself. The aim is to 
determine the logic and scope for provision of 
distinct 3D-printing legislation and for the early 
development of standards and guidance.
Extend hypothetical case scenarios to explore and  
test alternative, streamlined and rational approaches 
for demonstrating product comparability. As a basis 
for discussion with Competent Authorities, the aim is  
to develop proposals that could support regulatory 
approval for the addition of new manufacturing sites/
machines and for transferring multiple manufacturing 
processes and analytics to different geographical 
regions (pre- and post-MAA). 
Engage with appropriate stakeholders to consider 
and explore the scale of uncertainties and 
opportunities related to the impact of Brexit on the 
future UK regulatory and reimbursement environment 
and consequences for UK manufacturing and  
supply chains in the context of RDM. The aim is  
to realise opportunities to influence any national 
plans for adapting relevant regulations in the UK.
Establish an industry-wide initiative to explore 
solutions for recycling, energy reuse or greener 
manufacturing and disposal strategies to meet  
the expected increased reliance on the use  
of single-use components in bioprocessing.
Extend hypothetical case scenarios to explore  
and develop alternative manufacturing licensing 
models that consider new risk-based categories  
of manufacturing authorisation and inspection, 
which recognise the use of automated, closed-
system production platforms and the customisable 
nature of processes/products. As a basis for 
discussion with Competent Authorities, the aim  
is to develop proposals that envisage host sites 
becoming satellite manufacturing sites under  
a main central hub licence holder.
Review the CMC and design control requirements 
that currently apply to the conventional manufacture 
of combination ATMPs and Medical Devices under 
existing EU regulatory frameworks. The aim is to 
draw on hypothetical case scenarios to explore their 
applicability to 3D-printing and identify the actions 
required to reconcile the elements that relate to  
the customisability and unique build processes of  
3D printers, including unique post-print processes 
such as cleaning, finishing and sterilisation.
Drawing parallels with relevant custom-made 
device, Hospital exemption and ‘Specials’ regulatory 
pathways, establish a working group, with support 
from appropriate stakeholders, to identify where  
the limits of regulatory authority might apply to  
the product and service based elements of RDM. 
The aim is to delineate between ‘routine’ industrial 
manufacture and ‘non-routine’ manufacture of 
customisable 3D-printed devices in hospital settings 
and the regulatory/liability distinction between 
products that are ‘placed on the market’ or ‘put  
into service’ using representative case examples.
Establish an industry group, with support from 
appropriate stakeholders, to consider and develop 
guidance on the definition of closed-systems  
and the acceptability of closed-system processing  
in low-grade or controlled-not-classified spaces.  
As a key enabler for simplifying operating costs  
and facility design/re-engineering,  
commissioning and qualification, the aim is  
to test a new regulatory strategy where the  
host facility is treated as equipment for purposes  
of qualification and validation. 
Drawing upon representative 3D-bioprinting case 
examples, engage with appropriate stakeholders to 
identify the regulatory/liability boundaries between 
the customisable manufacturing process and the 
practice of medicine to define the specific activities 
that lie outside the bounds of regulatory jurisdiction.
R2 Transforming requirements for demonstrating  
product and process quality control and assurance
Drawing on the CMC review, extend hypothetical 
case scenarios to investigate the application  
of continuous quality verification methods as  
an alternative process validation approach.  
In line with the real-time product release 
philosophy, the aim is to develop proposals as  
a basis for discussion with Competent Authorities.
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Review the GMP/QS requirements that currently 
apply to the conventional manufacture of Medical 
Devices and combination ATMPs under existing EU 
regulatory frameworks. The aim is to design and 
develop a unified and streamlined Quality System 
that integrates the operational provisions for  
the manufacture of both the medical device and 
cellular constituent parts of 3D implantable products 
(i.e. for manufacturers making both constituent 
parts in the same facility).
Drawing upon the GMP/QS review, engage with 
appropriate stakeholders to explore how the 
principles of GMP and the associated inspection/
audit frameworks can be made more applicable  
to the parallel, aseptic manufacture of multiple 
cell-based products in automated, closed-system 
production platforms that can be operated in 
‘controlled-not-classified’ room environments.
Extend hypothetical case examples to develop  
and structure alternative approaches for justifying 
planned derogations from the requirements to  
hold retained and reference samples, for instance, 
in cases where the individualised or customised  
and MTO (‘batch of one’) nature of products  
make these requirements impractical or unfeasible. 
The aim is to develop proposals as a basis for 
discussion with Competent Authorities.
R3 Transforming procedures for governance in the chain of custody
Develop generalisable process maps to identify  
all the hand-off points in the chain of custody  
for representative hypothetical case scenarios  
to delineate the scope of product and process 
liabilities in the legal framework for the commercial 
manufacture of goods in hospital, franchise  
or home settings. The aim is to explore the 
transactional arrangements and opportunities to 
reduce or eliminate the liability exposure of multiple 
participants within the production and supply chain.
Extend the process mapping exercise to advance 
understanding of the additional regulatory/legal risk 
exposures related to data control, management and 
protection across multiple machines that incorporate 
the use of configurable or customisable, controlling 
software (CAD-CAM chain) in the printing process.
Establish an industry group, with support  
from appropriate stakeholders, to consider the 
translational level challenges for navigating  
away from batch-centric regulatory paradigms 
towards future pathways for regulatory approval  
of real-time release testing approaches.
Establish a working group to explore options for 
streamlining the chain of custody for traceability 
and release of goods, drawing on the process maps 
for hypothetical cases to delineate the regulatory/
legal obligations of the MAA licence holder and the 
host sites. The aim is to consider how an equal level 
of confidence in the quality and pharmacovigilance 
of released goods can be achieved through remote 
monitoring by centralised or regional QPs and to 
develop proposals as a basis for discussion with 
Competent Authorities.
Drawing on the process mapping exercise, establish 
a working group to consider and test hypothetical 
scenarios that can lead to failure modes in the chain 
of custody. The aim is to advance understanding of 
the risks related to unauthorised production, illicit 
use of raw materials/reagents, the potential for 
mix-ups in patient drug or dosing treatment 
regimens or the potential for off-label prescribing. 
This will provide the basis for assessing the severity, 
probability of occurrence and ability to detect risks 
across different business operational scenarios that 
leverage distributed cell-factory and 3D-printing 
production platforms and to identify opportunities 
to build in tamper-proof strategies.
Establish a working group to understand and 
identify disease areas and addressable target 
patient populations where economies of scope  
(the degree of product flexibility) can best be 
leveraged by the features of the cell micro-factory 
platform technology, accounting for future trends 
towards personalised and precision medicine.  
The aim is to provide a therapeutic framework  
for targeting platform-compatible CATBT  
product groups (number and type of products  
per facility) with sufficient value release for 
innovator companies, based on expected  
clinical benefits of each product candidate.
Establish working group to explore the number  
and location of potential treatment centres to 
identify the market channels where economies  
of scale and the business advantages can best  
be leveraged by the attributes of RDM. This  
must consider the potential need for complex 
interventional surgical procedures associated  
with some implantable devices. The aim is to 
provide a market framework for targeting the 
predominant prescribers, KOLs and payers in  
each channel where the 3D devices/products will  
be used most and where they will realise greatest 
revenue potential, considering the differing value 
propositions of the public/private healthcare 
networks (civilian and military), specialist pharmacies 
and the pharmaceutical manufacturers.
Develop a framework to broadly categorise and 
describe the potential clinical and economic value 
of expected patient benefits (e.g. magnitude of 
added value in terms of better clinical outcomes, 
improved patient satisfaction and access to new 
therapies etc.) based on the attributes of specific 
product candidate cases. The aim is to provide  
the theoretical foundation for an economic 
evaluation of product candidates, as precursor  
to the development of models to forecast pricing 
and revenue scenarios (on a per-patient basis)  
in current and potential market channels.
Establish working group to explore the number and 
location of potential treatment centres to identify 
the market channels where economies of scale (the 
degree and proximity of distribution) and business 
advantages can best be leveraged by the attributes 
of RDM. The aim is to provide a market framework 
for strategically targeting the predominant 
prescribers, key opinion leaders (KOL) and payers  
in each channel where the CATBT products will  
be used most and where they will realise greatest 
revenue potential, considering the differing value 
propositions of the public NHS system and the 
private healthcare networks (civilian and military).
Establish a working group to understand and 
identify the therapeutic areas and addressable 
target patient populations where economies  
of scope can best be leveraged by the features  
of the 3D-printing technology and service offering, 
accounting for the patient/product benefits 
conferred by the level of customisation and 
personalisation. The aim is to provide a  
therapeutic framework for targeting 3D 
applications with sufficient value release based  
on expected clinical benefit compared with  
current standard of care, including prosthetics, 
implants, fabricated tissues and organs, solid 
dosage forms and medical devices.
O1 Constructing a quantifiable value proposition for market access
B4 Operational Research & Development  
Priorities for Redistributed Manufacturing
Frameworks for Business Model and  
Organisational Transformation
68  RiHN RiHN  69
Develop advanced system and organisational  
level models to describe and map the different 
operational business scenarios for creating and 
delivering value through implementation of 
centralised or RDM approaches that leverage  
cell micro-factory and 3D printing technologies.  
The aim is to provide a framework to support  
a quantitative and comparative evaluation  
(e.g. cost-benefit, cost-effectiveness and/or 
cost-utility analysis) of the economic value of the 
expected benefits to the hospital and the broader 
healthcare system that RDM confers, compared 
with conventional centralised product provision. 
This will provide the basis for impact-led case 
studies with market access stakeholders.
Develop an organisational framework to broadly 
categorise and describe the type and location  
of interactions between the customer (as the 
manufacturer) and the central supplier (machine 
producer and/or franchise). The aim is to provide 
the basis for mapping the customer-touch points  
in each selected market channel. This serves as  
a precursor for identifying potential barriers to 
servitisation and opportunities for aligning internal 
processes and capabilities to enhance customer 
relationships for different operational business 
scenarios for RDM.
Develop and configure advanced system and 
organisational level models to map a range of 
operational business convergence scenarios for 
adoption of 3D-printing as a complementary 
manufacturing system for the pharmaceutical 
industry. The aim is to provide the basis for  
impact-led collaborative case studies to test such 
hybrid systems for specific niche applications and 
analyse opportunities for extending value in existing, 
conventional pharmaceutical pipelines and supply 
chains. This may cover the customisation of existing 
solid dosage forms and reduction of material wastage.
Cross-industry regulatory case studies to  
examine the status of adoption of 3D-printing  
(e.g. in automotive, aerospace, defence industries 
as early adopters) to identify and address potential 
barriers to the adoption of 3D-printing technology 
as a complementary manufacturing system in the 
pharmaceutical sector.
O2 Establishing customer interfaces and pathways for adoption
Establish a multi-perspective working group 
(industry, NICE, NHS, government representatives) 
to consider the healthcare market challenges  
to adoption of manufacturing technologies and 
commercial operations in hospital settings to  
gauge the impact of external supply-side factors, 
external demand-side factors and internal health 
service factors on adoption decisions. The aim is  
to provide a framework to develop realistic  
decision tools to support and incentivise technology 
adoption. This is a prerequisite for identifying 
optimal pathways for adoption and for development 
of models to forecast market uptake/penetration  
rates that are needed to optimise capital 
expenditure and incentivise investment in 
technology development.
Establish a working group (industry, NICE,  
NHS, government representatives) to review  
and investigate opportunities to exploit existing  
and emerging initiatives, including the  
Accelerated Access Review (AAR), NICE modelling 
and NHS specialised commissioning programmes,  
as potential pathways for adoption and market access.
Investigate potential future opportunities to exploit 
the Accelerated Access Pathway proposed by the 
AAR for early implementation of selected  
RDM advanced therapy focused pilots. 
Establish working group to define the products, 
services, partnership arrangements and supporting 
infrastructure (Product Service System) required  
to implement and deliver the level and extent of 
servitisation required to navigate the customer-
centric solution space (e.g. the user driven, 
customised or personalised product design space). 
The aim is to develop and test new manufacturing 
organisational models that provide optimal benefits 
for the innovator company and for the customer.
Establish a working group to consider the challenges 
to forming the collaborative partnerships with the 
NHS that will be required to build capacity for RDM. 
This should examine reconfiguration of supply chains 
and logistics, viability of business models, and the 
role of hospitals to support the commercial 
manufacture and formulation of advanced  
therapies. The aim is to support ongoing  
discussions to establish a network of Cell  
and Gene Therapy Treatment Centres.
Engage with stakeholders from regional healthcare 
trusts to further explore opportunities to develop 
and implement a pilot regional Hub for the provision 
of aseptic goods manufacturing and supply 
services. The aim is to build on the concept of  
a ‘Collaborative Enterprise Network’ that has 
previously been developed and trialled with 
Midlands NHS Trust stakeholders, as a basis  
for forming a network of similar hubs in other  
parts of the UK.
Establish a working group to extend the analysis of 
supply models to identify and assess the regulatory/
legal risks related to infrastructure and product/
service lifecycle management and governance. This 
provides a risk-based framework for developing 
models of servitisation and for implementation of 
information system solutions, with the aim  
of mitigating exposure to regulatory risk and 
administrative burden across sites and optimising 
the degree of autonomy of each hospital site  
in the network.
Supported by cross-industry case studies (e.g. 
aerospace, defence industries), explore the 
information technology and Industry 4.0 landscape 
to determine the core enablers for establishing  
the interconnectivity between discrete aspects  
of the RDM supply chain models and the industrial 
operational environment. The aim is to identify 
where the principles can be applied to the deployment 
of the production technology and the organisation 
of the service-orientated infrastructure. 
Engage with stakeholders to implement in-depth 
mapping and analysis of existing healthcare 
delivery configurations and NHS supply networks 
(including national/regional cell and tissue 
transplantation supply chains, national blood  
supply chains, hospital pharmacy networks, 
prosthetic networks and national networks  
for personalised medicine). The aim is to  
identify and stratify current physical and digital 
infrastructure capacity/capability constraints  
and human resource capability gaps that underpin 
the main processes linked to a foundational state  
of institutional readiness.
Draw on outcomes from NHS supply network  
gap analysis to establish the core capability and 
infrastructure requirements (at facility and network 
levels) and provide a basis for evaluating the scale, 
scope and cost of raising the level of institutional 
readiness for deployment (installation, set-up  
and operation) of supplied commercial cell  
micro-factory or 3D-printing production systems  
in hospital settings.
O3 Reconfiguring the organisational value system
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Establish a cross-functional working group 
(customers and technology partners) to create an 
initial pilot project to establish proof of concept, 
targeting the transfer of a selected manufacturing 
technology prototype (e.g. 3D-printer) into one or 
two hospital sites and market channels. The aim  
is to gain real-world insights into the vertical  
and horizontal operational processes and  
functional workflows that need to be implemented 
and integrated to enable routine commercial 
manufacturing in a hospital setting.
Establish an industry group to design and develop 
new manufacturing skills packages and delivery 
mechanisms to grow a technician and operator 
workforce capable of reliably running routine 
manufacturing operations. The aim is to deliver 
responsive programmes across future sector-
specific RDM-enabling production platforms, 
leveraging existing or proposed broader skills 
development initiatives.
O4 Designing commercially viable financial structures
Establish a pre-competitive working group to 
develop new cost modelling methodologies to 
categorise and quantify the cost elements for 
implementing and operating centralised and 
redistributed manufacturing and supply 
approaches that leverage cell micro-factory 
production platform technologies for the 
manufacture and delivery of autologous and/or 
allogeneic CATBTs. In the context of hypothetical 
case examples, the aim is to provide the basis for  
a comparative analysis of cost structures, in terms  
of accurately quantifying the proportion of fixed 
and variable costs to total costs and the factors that 
influence the final pricing strategy. The outcomes 
will provide a consensus view on which redistributed 
operational business scenarios can confer 
commercially viable economies of scale and scope 
for maximising revenue and in so doing create the 
confidence that underpins the required investment 
in the development of RDM strategies for CATBTs. 
Develop new methodologies to build an 
experimental data-driven framework to categorise 
and quantify the cost elements for implementing 
and operating centralised and redistributed 
manufacturing and supply approaches that 
leverage 3D-printing technologies. In the context  
of hypothetical case examples, the aim is to provide 
the experimental basis for the development of cost 
structures that accommodate hidden costs related 
to ancillary manual processes and to the risk of build 
failure or part rejection.
Establish a market access stakeholder working 
group to consider how the unique clinical and 
economic performance attributes of the 
redistributed product-service dimension of 
therapeutic models may challenge conventional 
healthcare valuation and reimbursement decision 
frameworks; for instance, by conferring 
proportionate benefits to both the patient  
and the healthcare system aggregated across 
distributed sites. The aim is to provide the basis  
for establishing a common language and evaluation 
criteria to aid understanding of the ways RDM 
represents value for money and for identifying 
stakeholder concerns/barriers to uptake of  
RDM approaches across the healthcare system.
Establish a product data interoperability group  
to develop digital platforms for standardising  
the collection of patient-specific 3D-printed drug 
performance data. The aim is to build a real-time, 
visible database for individual patients to enable 
patient-specific formulations and dosages to be 
adjusted according to phenotypic evidence of 
intended results and undesirable side effects.
Drawing on a review of existing initiatives in the  
field of advanced therapies, hypothetical case 
scenarios should be extended to investigate 
alternative payment and financing models that  
can be tailored to the specific attributes of the 
product groups targeted for RDM in hospital 
settings or other market channels. As a prerequisite 
to engaging market access stakeholders, the aim  
is to provide a decision framework to explore and 
develop models that are implementable in short/
mid-term timeframes. This must adequately 
consider value relative clinical and economic 
benefits, management of shared risk between 
multiple stakeholders, the need to minimise patient/
caregiver economic burden and up-front cost, and 
patient access affordability. Outputs should provide 
the precursor to the development of proposals/
recommendations as a basis for discussion with 
market access stakeholders to further define and 
prioritise the necessary steps to address legislative 
and logistical barriers to implementation.
Establish product data interoperability group to 
develop digital platforms for standardising the 
collection of product performance data (i.e. clinical 
trial, product release and post-marketing data)  
in aggregate and for individual patients. The aim  
is to build a real-time, visible therapeutic network  
to accelerate clinical experience that (with 
appropriate permissions and data safeguards) 
could be shared with public and private payers  
in performance-based arrangements and 
coordinate pull-through and market access  
across distributed sites.
O5 Establishing viable routes to EU market access
Establish an industry group, supported by 
appropriate NHS stakeholders, to develop 
responsive programmes to address relevant future, 
sector-specific product technology skills and 
knowledge gaps of current and future clinical 
professionals. The aim is to align and leverage 
existing strategies and training programmes to 
advance the R&D knowledge and skills base among 
the NHS workforce (e.g. NIHR research training 
programmes for clinical professionals and NHSE 
personalised medicine strategy). This underpins the 
need to encourage greater involvement of the next 
generation of clinical professionals, pharmacists, 
prosthetists and surgeons in commercial R&D 
functions for emerging regenerative medicine 
therapies and 3D-printed medicines.
Extend models for forecasting market uptake/
penetration to establish the projected 
manufacturing capacity required to support  
access to current and potential UK markets.  
The aim is to provide the experimental basis for 
establishing the optimal economy of scale and rate 
of capital expenditure to mitigate investment risk in 
capital equipment acquisition and/or facility build.
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RESEARCH CHART: 
LINKING NEEDS, CHALLENGES  
& FUTURE PRIORITIES FOR R&D
This diagram illustrates the systematic linkages  
between the ‘needs’ driving RDM, ‘challenges’  
(Appendix A) that need to be overcome and  
‘priority areas’ for future R&D (Appendix B);  
covering cell microfactories and 3D-printing.
Codes with A1, A1-2, A2, A3, A4 correspond with Appendix A1, A1-2, A2, A3, A4
Codes with I1, I2, I3 correspond to Appendix B1
Codes with I4, I5, I6, I7, I8 correspond to Appendix B2
Codes with R1, R2, R3 correspond to Appendix B3
Codes with O1, O2, O3, O4, O5 correspond to Appendix B4
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Creating the skills and capability base for new production system architects
Limited supply chain capacity and capability to support standardised platform design 
Gaps & fragmentation of technical/engineering industry standards for platform system design and configuration
High capital cost presents significant investment risk & disincentive for early automated production platform development 
Functional capability immaturity and limited performance & interoperability of underlying enabling technologies 
Lack of consensus on industry standards for use, interoperability, governance & validation of manufacturing machine data
Interchangeable manufacturing relies on specifying more quantitative CQAs that are related to product function 
Lack of multi-scale computation & predictive modelling tools to support design verification/validation
Incompatibilities with existing materials quality testing standards 
Uncertainties & ambiguities related to regulatory governance of customisable CAD/CAM systems & processes 
Uncertainties & ambiguities related to regulatory governance of closed-system production technologies/processes 
Multicentre manufacturing models are subject to substantial comparibility requirements & the need for multiple MAs 
Unclear legal/regulatory provisions for managing process/product liabilities in a shared & distributed chain of custody 
Unclear legal/regulatory provisions for control, management and security of data transferred across sites/individuals 
Incompatibility of real-time release approaches with conventional batch-centric regulatory paradigms 
Geographic disparities in clinical, manufacturing and supply chain regulatory standards 
Expanding skills and capability base for regulatory/QP professionals 
Value propositions that dictate optimal production platform design and mode of operation are unproven 
Significant healthcare system barriers to technology adoption and commercial operations in healthcare settings 
Raising the level of organisational capability readiness for deployment of technologies, services & manufacturing operations 
Skills, capability and training gaps for geographically dispersed production workforceof operators/technicians 
Skills, capability and training gaps for next-generation clinical professionals 
Incompatibilities with conventional and geographical divergent valuation, payment & financial models
Optimising cost structures & defining cost/benefit thresholds that maximise price potential and revenues 
Building the manufacturing infrastructure and workforce
Advancing production system readiness
Advancing post-production system readiness
Building digital assurance infrastructures
Advancing real-time (RT) process characterisation and control analytical technology readiness
Advancing real-time (RT) product characterisation analytical technology readiness
Advancing assurance of manufacturing quality
Advancing data management and information technology readiness
Developing viable regulatory strategies for re-distributed manufacturing and the underlying technologies
Transforming product and process quality control and assurance procedures
Transforming procedures for governance of the chain of custody
Constructing a quantifiable and compelling value proposition for market access
Establishing customer interfaces and pathways for adoption
Reconfiguring the organisational value system
Designing commercially viable financial structures
Establishing viable routes to EU market access
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FOLLOW THE DISCUSSION
Follow us on Twitter
#EPSRCRIHN
Follow us on LinkedIn
The Redistributed Manufacturing  
in Healthcare Network (RiHN)
FOR MORE INFORMATION CONTACT
University of the West of England
Bristol Business School BS16 1QY
T +44 (0)117 32 82297
E info@rihn.org.uk
www.rihn.org.uk
